



Aalborg Universitet

AALBORG UNIVERSITY  
DENMARK

## NEW PHARMACOLOGICAL TREATMENT TO PRESERVE/IMPROVE RENAL FUNCTION AFTER PARTIAL NEPHRECTOMY

Brignone, Juan Ignacio

DOI (link to publication from Publisher):  
[10.54337/aau679680103](https://doi.org/10.54337/aau679680103)

Publication date:  
2023

Document Version  
Publisher's PDF, also known as Version of record

[Link to publication from Aalborg University](#)

Citation for published version (APA):  
Brignone, J. I. (2023). *NEW PHARMACOLOGICAL TREATMENT TO PRESERVE/IMPROVE RENAL FUNCTION AFTER PARTIAL NEPHRECTOMY*. Aalborg Universitetsforlag.  
<https://doi.org/10.54337/aau679680103>

### General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

### Take down policy

If you believe that this document breaches copyright please contact us at [vbn@aub.aau.dk](mailto:vbn@aub.aau.dk) providing details, and we will remove access to the work immediately and investigate your claim.



**NEW PHARMACOLOGICAL TREATMENT TO  
PRESERVE/IMPROVE RENAL FUNCTION  
AFTER PARTIAL NEPHRECTOMY**

**BY  
JUAN IGNACIO BRIGNONE**

DISSERTATION SUBMITTED 2023



**AALBORG UNIVERSITY**  
DENMARK



**NEW PHARMACOLOGICAL  
TREATMENT TO PRESERVE/IMPROVE  
RENAL FUNCTION AFTER PARTIAL  
NEPHRECTOMY**

**BY  
JUAN IGNACIO BRIGNONE**



**AALBORG UNIVERSITY**  
DENMARK

DISSERTATION SUBMITTED 2023

Dissertation submitted: July 2023

PhD supervisors: Clinical Associate Professor Brian Kloster  
Aalborg University Hospital  
Professor Lars Lund  
Odense University Hospital

PhD committee: Professor Jeppe Hagstrup Christensen (chair)  
Aalborg University, Denmark  
Professor Andreas Røder  
Rigshospitalet, Denmark  
Professor Jenny Nyström  
University of Gothenburg, Sweden

PhD Series: Faculty of Medicine, Aalborg University

Department: Department of Clinical Medicine

ISSN (online): 2246-1302  
ISBN (online): 978-87-7573-801-4

Published by:  
Aalborg University Press  
Kroghstræde 3  
DK – 9220 Aalborg Ø  
Phone: +45 99407140  
aauf@forlag.aau.dk  
forlag.aau.dk

© Copyright: Juan Ignacio Brignone

Printed in Denmark by Stibo Complete, 2023

|    |  |                  |
|----|--|------------------|
| 45 | <b>TABLE OF CONTENTS</b>   |                  |
| 46 | <b><u>PREFACE .....</u></b>  | <b><u>4</u></b>  |
| 47 | <b><u>TABLE OF ABBREVIATIONS.....</u></b>  | <b><u>5</u></b>  |
| 48 | <b><u>ENGLISH SUMMARY .....</u></b>  | <b><u>8</u></b>  |
| 49 | <b><u>DANSK RESUME .....</u></b>   | <b><u>10</u></b> |
| 50 | <b><u>ACKNOWLEDGEMENTS.....</u></b>  | <b><u>12</u></b> |
| 51 | <b><u>INTRODUCTION.....</u></b>  | <b><u>13</u></b> |
| 52 | <b><u>KIDNEY PHYSIOLOGY .....</u></b>  | <b><u>13</u></b> |
| 53 | RENAL CLEARANCE .....  | 13               |
| 54 | REGULATION OF RENAL BLOOD FLOW AND GLOMERULAR FILTRATION RATE.....                       | 14               |
| 55 | <b><u>INTRODUCTION TO KIDNEY CANCER AND PARTIAL NEPHRECTOMY WITH THE USE OF WARM</u></b> |                  |
| 56 | <b><u>ISCHEMIA.....</u></b>  | <b><u>15</u></b> |
| 57 | EPIDEMIOLOGY .....   | 15               |
| 58 | ETIOLOGY .....   | 16               |
| 59 | TYPES OF RCC.....  | 16               |
| 60 | SYMPTOMS AND DIAGNOSIS.....  | 17               |
| 61 | CLASSIFICATION .....   | 18               |
| 62 | TREATMENT .....  | 18               |
| 63 | ADAPTIVE CHANGES FOLLOWING PARTIAL OR TOTAL NEPHRECTOMY .....                            | 21               |
| 64 | <b><u>NATRIURETIC PEPTIDES .....</u></b>   | <b><u>23</u></b> |
| 65 | EFFECTS ON SODIUM/VOLUME REGULATION AND BLOOD PRESSURE OF NATRIURETIC PEPTIDES .....     | 23               |
| 66 | EFFECTS OF NATRIURETIC PEPTIDES AT KIDNEY LEVEL.....                                     | 24               |
| 67 | <b><u>ANIMAL MODELS TO EVALUATE KIDNEY FUNCTION .....</u></b>                            | <b><u>25</u></b> |
| 68 | <b><u>HYPOTHESIS AND AIMS: .....</u></b>   | <b><u>26</u></b> |
| 69 | <b><u>ANIMAL LEGISLATION AND ETHICS .....</u></b>  | <b><u>27</u></b> |
| 70 | <b><u>MATERIAL AND METHODS.....</u></b>  | <b><u>28</u></b> |
| 71 | STUDY 1.....   | 28               |
| 72 | STUDY 2.....   | 29               |
| 73 | STUDY 3.....   | 34               |

|    |   |                  |
|----|---|------------------|
| 74 | <b><u>RESULTS.....</u></b>              | <b><u>36</u></b> |
| 75 | STUDY 1.....                            | 36               |
| 76 | STUDY 2.....                            | 39               |
| 77 | STUDY 3.....                            | 47               |
| 78 | <b><u>DISCUSSION .....</u></b>          | <b><u>53</u></b> |
| 79 | STUDY ONE .....                         | 53               |
| 80 | STUDY TWO .....                         | 55               |
| 81 | STUDY THREE .....                       | 58               |
| 82 | <b><u>OVERALL CONCLUSIONS .....</u></b> | <b><u>60</u></b> |
| 83 | <b><u>PERSPECTIVES .....</u></b>        | <b><u>60</u></b> |
| 84 | <b><u>LIST OF REFERENCES .....</u></b>  | <b><u>62</u></b> |

85

86

87

88

89

90

91

92

93

94 **PREFACE**

95 This PhD study was conducted during my employment as a PhD fellow at the Department of Clinical Medicine  
 96 at Aalborg University and the Department of Urology at Aalborg University Hospital Nord, Denmark, in the  
 97 period from September 2018 to March 2022.

98 The research was supervised by Senior Registrar, Clinical Associate Professor Brian Kloster from Aalborg  
 99 University Hospital and Professor Lars Lund from the Department of Urology at Odense University Hospital.

100 The content of the thesis is based on three papers written during this period:



- 101 1. Protection of kidney function and tissue integrity by pharmacologic use of natriuretic peptides and neprilysin  
 102 inhibitors. Brignone J, Assersen KB, Jensen M, Jensen BL, Kloster B, Jønler M, Lund L. Pflugers Arch. 2021  
 103 Apr;473(4):595-610. doi: 10.1007/s00424-021-02555-w. Epub 2021 Apr 12. PMID: 33844072.  
 104  
 105  
 106 2. Protective effect of sacubitril/valsartan (Entresto®) on kidney function and filtration barrier injury in a porcine  
 107 model of partial nephrectomy. Brignone J, Jensen M, Jensen BL, Assersen KB, Goetze JP, Jødal L, Andersen TB,  
 108 Magnusdottir SO, Kloster B, Jønler M, Lund L. Nephrol Dial Transplant. 2022 Jun 15:gfac200. doi:  
 109 10.1093/ndt/gfac200. PMID: 35704678.  
 110  
 111  
 112 3. Kidney volume increase following unilateral nephrectomy relates to plasma natriuretic peptide. Juan Brignone,  
 113 Boye L Jensen, Mia Jensen, Claus Bistrup, Jens P. Goetze, Nessn Azawi and Lars Lund (submitted to BMC  
 114 Nephrology Journal)

115

116

117

118

119

120

121 **TABLE OF ABBREVIATIONS**

122 AKI: Acute kidney injury

123 ANG: Angiotensin

124 ANOVA: Analysis of variance ANP: Atrial natriuretic peptide

125 ARNI: Angiotensin-renin-neprilysin-inhibitors

126 AS: Active surveillance

127 AUC: Area under the curve

128 BMI: Body Mass Index

- 129 BNP: Brain natriuretic peptide
- 130 CI: Confidence interval
- 131 cGMP: Cyclic guanosine monophosphate
- 132 CKD: Chronic kidney disease
- 133 CN: Cytoreductive nephrectomy
- 134 CNP: C-type natriuretic peptide
- 135 CT: Computed tomography
- 136 DPTA: Diethylenetriaminepentaacetic acid
- 137 EDTA: Ethylenediaminetetraacetate
- 138 ESKD: End-stage kidney disease
- 139 Fr: French
- 140 GFR: Glomerular filtration rate
- 141 HU: Hounsfield units
- 142 KIM: Kidney-injury molecule 1
- 143 MAP: Mean arterial pressure
- 144 MBq: Million Becquerels
- 145 MRI: Magnetic resonance image
- 146 MR-proANP: Mid-regional pro-hormone atrial natriuretic peptide
- 147 NEP: Neutral endopeptidase
- 148 NO: Nitric oxide
- 149 NP: Natriuretic peptide
- 150 NPR-A: Natriuretic peptide receptor type A
- 151 NPR-C: Natriuretic peptide receptor type C
- 152 NRP-B: Natriuretic peptide receptor type B
- 153 NT proBNP: N-terminal pro-hormone brain natriuretic peptide
- 154 LCZ696: Sacubitril/Valsartan or Entresto®
- 155 PN: Partial nephrectomy
- 156 RAAS: Renin angiotensin-aldosterone system

- 157 RBF: Renal blood flow
- 158 RCC: Renal cell carcinoma
- 159 RN: Radical nephrectomy
- 160 SD: Standard deviation
  
- 161 SE: Standard Error
  
- 162 Tc: Technetium
  
- 163 TN: Total nephrectomy
  
- 164 TNM: Tumour-Node-Metastasis
- 165 VHL: Von-Hippel-Lindau
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174

175 **ENGLISH SUMMARY**

176 The prevalence of renal cancer is increasing, which may, among others, be due to a rise in the number of radiological  
 177 investigations performed for other reasons, e.g., to determine the origin of abdominal pain or weight loss. Recent years have  
 178 therefore seen an increase in the number of surgical interventions involving the kidneys. This trend and the rapid aging of the  
 179 general population command careful considerations of possible treatments and strategies to protect the renal function during  
 180 and after kidney surgery. Searching for a feasible therapeutic option that avoids or at least minimizes post-surgery loss of  
 181 kidney function, we conducted studies to evaluate the role of natriuretic peptides and blockage of their degradation as this  
 182 approach has shown promising results in the cardiovascular area.

183 The group of NPs counts three vasoactive peptides with a molecular weight below 10 kDa. that are structurally interrelated;  
 184 they are atrial NP (ANP), B-type NP (BNP), and C-type NP (CNP). NPs are synthesised, stored and secreted at  
 185 myocardiocyte level.

186 Aims:

- 187 a) To perform a review to determine the potential benefits of the use of NPs and angiotensin-receptor-neprilysin  
 188 inhibitor (ARNI) drugs to protect kidney function.
- 189 b) To determine the feasibility of single kidney glomerular filtration rate (GFR) measure using <sup>99m</sup>Tc  
 190 diethylenetriaminepentaacetic acid (DTPA) as radiotracer in a pilot study, using pigs as an animal model.
- 191 c) To perform a randomised pre-clinical study investigating the action of LCZ696 at the kidney level after laparoscopic  
 192 partial nephrectomy with prolonged ischemia time.
- 193 d) To elucidate the role of NPs in the mechanism of kidney hypertrophy after partial or total nephrectomy.

194 Results and conclusions

- 195 a) Having conducted an extensive review, we conclude that the main functions of these peptides at kidney level are to  
 196 promote water and sodium excretion and to increase renal blood flow. Continuous ANP infusion above physiological  
 197 levels induces vasodilatation of arcuate and afferent vessels and constriction of efferent arterioles, maintaining  
 198 oxygen supply at the medullary level. In addition, NP administration increased GFR and diuresis, but with a stable  
 199 filtration fraction. This effect is of vital importance since the concomitant increase of GFR and filtration fraction are

200 interpreted as detrimental effects in acute kidney injury (AKI) scenarios because the increased transport of filtered  
 201 sodium is linearly correlated with oxygen usage, dramatically increasing oxygen consumption.

202 b) Six pigs were injected with a known quantity of [Tc-99m] Tc-DTPA, with 12 blood samples drawn from 5 to 240  
 203 minutes after injection. GFR was determined as injected activity divided by area under a bi-exponential  
 204 fit to the plasma concentration curve. Additionally, we determined GFR by total and single kidney clearance of [Tc-  
 205 99m] Tc-DTPA by collection of urine from the bladder and single kidney respectively. The results were within +/- 2  
 206 standard deviations (SD) = +/- 6% of the value from the bi-exponential fit and had only a single outlier. Based on  
 207 these finding, our conclusion is that in pigs, GFR can be reliably determined with a simplified procedure similar to  
 208 the one used for humans.

209 c) We performed a prospective randomised animal study and tested the possible protective effect of NPs at kidney level  
 210 using angiotensin II receptor- neprilysin inhibitor LCZ696 = Entresto® before, during and after partial nephrectomy.  
 211 In the group of PN+ Entresto® treatment for 15 days, one of the main findings was a GFR increase in the non-injured  
 212 kidney and protection of the kidney filtration barrier in both kidneys.

213 d) In our observational sub-study with follow up in patients subjected to partial or radical nephrectomy, we evaluated  
 214 NPs in plasma and kidney hypertrophy association in the compensatory post-operative kidney hypertrophy. Patients  
 215 undergoing radical nephrectomy experienced an average increase of 27% on the remnant kidney volume one year  
 216 after surgery. The NPs, especially *mid regional-proANP* (precursor of ANP) showed significant association to this  
 217 phenomenon through direct positive correlation with volume gain after total nephrectomy.

218  
 219 Concluding perspective

220 In perspective, combined AT1 receptor and neprilysin inhibition is a promising approach for long-term renal protection in  
 221 addition to AT1 receptor blockers in AKI and chronic kidney disease. Therapy with a focus on NPs seems to be auspicious,  
 222 and our studies could represent a starting point for future investigations. We are aware that larger clinical trials are needed for  
 223 definitive conclusions.

226 **DANSK RESUME**

227 Antallet af nyrekræfttilfælde er stigende. Dette skyldes bl.a. de mange radiologiske undersøgelser, der udføres af andre  
 228 grunde, f.eks. for at afdække årsagen til mavesmerter eller vægttab. Dette har medført et stigende antal kirurgiske  
 229 nyreindgreb. Tendensen med hyppigere kirurgisk behandling af nyretumorer har sammen med aldringen af den generelle  
 230 befolkning affødt et behov for at evaluere mulige behandlinger og strategier for at beskytte nyrefunktionen under og efter  
 231 nyrekirurgi. Tidligere forskning har vist, at natriuretiske peptider og blokering af deres nedbrydning har lovende  
 232 perspektiver i forhold til behandling af kardiovaskulære lidelser. Vi ønskede derfor at undersøge, om disse perspektiver også  
 233 findes for nyresygdomme, specifikt om tab eller reduktion af nyrefunktion kan undgås.

234 Gruppen af natriuretiske peptider (NP) består af tre vasoaktive peptider med en molekylvægt på mindre end 10 kDa, som er  
 235 strukturelt forbundne; atrielt natriuretisk peptid (ANP), B-type natriuretisk peptid (BNP) og C-type natriuretisk peptid  
 236 (CNP). NP'er syntetiseres, lagres og udskilles på myokardiocytniveau.

237 **Mål:**

238 a) At foretage et systematisk review og på baggrund af dette bestemme potentielle fordele ved brugen af natriuretiske peptider  
 239 og angiotensin-renin-neprilysin-hæmmere (ARNI).

240 b) At bestemme gennemførligheden af målinger af nyrens glomerulære filtrationshastighed (GFR) ved hjælp af <sup>99m</sup>Tc-  
 241 DPTA som radiotracer i en grisedyremodel.

242 c) At udføre en randomiseret præklinisk undersøgelse af virkningen af LCZ696 på nyreniveau efter laparoskopisk partiel  
 243 nefrektomi med forlænget iskæmitid.

244 d) At belyse NP mekanismernes rolle for nyrehypertrofi efter delvis eller total nefrektomi.

245 **Resultater**

246 a) Efter en omfattende litteraturgennemgang kan vi konkludere, at på nyreniveau er disse peptiders hovedfunktion at fremme  
 247 vand- og natriumudskillelse, samt at øge nyregennemblødningen. Kontinuerlig infusion af ANP over fysiologiske niveauer  
 248 inducerer vasodilatation af de afferente arterioler og indsnævring af efferente arterioler, der opretholder ilttilførslen på  
 249 medullært niveau. Derudover fører administration af NP'er til en stigning i GFR og diurese, men med stabil  
 250 filtreringsfraktion. Denne effekt er af afgørende betydning, da den samtidige stigning af GFR og filtreringsfraktionen tolkes

251 som en skadelig effekt i scenarier med akut nyresygdom, fordi den øgede transport af filtreret natrium er lineært korreleret  
252 med iltforbruget, hvilket øger iltforbruget dramatisk.

253 b) I alt blev 6 grise injiceret med en kendt mængde [Tc-99m]Tc-DTPA, hvorefter der blev taget 12 blodprøver fra 5 til 240  
254 minutter efter injektionen. GFR blev bestemt som injiceret aktivitet divideret med areal under en bi-eksponentiel tilpasning  
255 til plasmakoncentrationskurven. Resultaterne lå inden for  $\pm 2$  standarddeviationer (SD) =  $\pm 6\%$  af værdien fra den bi-  
256 eksponentielle tilpasning og med kun en enkelt outliner.

257 Konklusion: Hos grise kan GFR bestemmes pålideligt med en forenklet procedure svarende til proceduren, der anvendes hos  
258 mennesker.

259 c) Vi udførte en prospektiv randomiseret dyreundersøgelse og testede den mulige beskyttende effekt af NP'er på nyreniveau  
260 baseret på brugen af angiotensin-renin-neprilysin-hæmmere (ARNI-lægemidler = Entresto®) før, under og efter partielle  
261 nefrektomier. Et af hovedfundene i gruppen af PN+ Entresto® i løbet af 15 dage var en stigning af GFR i den ikke-skadede  
262 nyre og beskyttelse af nyrefiltreringsbarrieren fra begge nyrer.

263 d) I vores observationsstudie med patienter udsat for partiel eller radikal nefrektomi ønsker vi at evaluere rollen af NP'er i den  
264 kompensatoriske mekanisme for postoperativ nyrehypertrofi. I gennemsnit oplevede de patienter, der blev udsat for radikal  
265 nefrektomi, en stigning på 27% på den resterende nyre et år efter operation. De natriuretiske peptider, især mid-regional-  
266 proANP (forløber for ANP), synes at være forbundet med dette fænomen og havde en stærk positiv korrelation med  
267 volumenforøgelse efter total nefrektomi.

268 Konklusioner

269 Ud over AT1-receptorblokkere synes kombineret AT1- og neprilysinhæmning at være en lovende tilgang til langsigtet  
270 nyrebeskyttelse ved akut nyreskade og kronisk nyresygdom. Terapien med fokus på NP'er ser ud til at være gunstig, og vore  
271 undersøgelser kan være et udgangspunkt for fremtidige undersøgelser. Vi er klar over, at der er behov for større kliniske  
272 forsøg, før der kan drages endelige konklusioner.

273

274

275

## 276 ACKNOWLEDGEMENTS

277 I wish to thank especially:

278 My immense gratitude goes to **Lars Lund** who has the gift of seeing beyond barriers (language, culture and others) and  
279 allowed me to move to and work in Denmark. Besides teaching me important aspects about science, you carried the enormous  
280 responsibility of making me and my family comfortable during this academic journey.

281 **Boye Jensen**; it was an honour for me and a catalyst for my career to share time with you. The positivism that you transmit  
282 has been extremely important, especially when I was unable to see the light at the end of the tunnel. Thanks for letting me be  
283 a remote part of your research unit, and thanks for introducing me to such talented people at the Department of  
284 Cardiovascular and Renal Research from the University of Southern Denmark; special thanks to **Mia Jensen and Kasper**  
285 **Bostlund Assersen** that shared experienced counselling and time during this PhD.

286 MD, PhD **Fernando Secin** from Argentina, who always shared his knowledge and helped me during my formation as a  
287 urology specialist. You have always encouraged me to take the next step towards better education and to leave the comfort  
288 zone, but most importantly, you have been always there (far but close) when I needed counselling or words of support.  
289 Thanks once again for believing in me when Lars Lund told you about this ambitious plan and asked you for a PhD fellow.

290 To **Jane Gamelgaard Petterson and Johan Poulsen**; thanks for the countless opportunities to develop my surgical skills  
291 during our days together at the operation room and at ROC Nord training centre, but most importantly, thanks to you and  
292 your beloved ones for letting us feel as part of your families.

293 To **Nessn Azawi**, thanks for sharing your experience, knowledge and way of working.

294 I would also like to thank my colleagues from the Department of Urology at Aalborg University Hospital. I vividly remember  
295 my first day here as if it were only yesterday; they received me with arms wide open and made me feel as if I were at home.

296 I want also to thank the staff from the Biomedical Laboratory and the Department of Nuclear medicine at Aalborg University  
297 Hospital, specially to **Lars Jødal, Sigríður Magnusdóttir and Nicholas Schandorph Nielsen**; without their help, it would be  
298 impossible to conduct this project.

299 A special thanks to my wife, Virginia, and our twins, Pia and Mateo, who spread happiness and joy every day when I came  
300 back home and who motivated me to always accept new challenges.



**301 INTRODUCTION****302 KIDNEY PHYSIOLOGY**

303 The nephron is the functional unit of the kidney. It consist of a glomerulus, formed by a renal corpuscle (within Bowman's  
304 capsule), a proximal tubule, the loop of Henle, a distal tubule and a collecting duct system[1, 2]. The glomerular unit receives  
305 the blood supply from the afferent arteriole, and the product of the filtration returns into the efferent arteriole. Each kidney  
306 counts approximately 1 million functional units, but this amount decreases dramatically with age, e.g. only 50% of the  
307 functional units remain at the age of 70 years[1]. The primary function of the glomerulus is to ultrafiltrate the blood plasma at  
308 an average rate of 125 ml/min in healthy young people. This ultrafiltration process refers to a passive mechanism of fluid  
309 movement with fewer proteins than in plasma[1]. The filtration barrier is formed by the capillary endothelium, the basement  
310 membrane and the foot processes of the podocytes (thick endothelial cell in contact with Bowman's capsule)[1]. This barrier  
311 allows the free passage of water, Na<sup>+</sup>, urea and glucose. However, it is not permeable to large proteins such as albumin, red  
312 blood cells, white blood cells or platelets[1]. The membrane avoids the permeability of proteins not only by size, but also as a  
313 charge-selective filter[1]. In addition to this filtration function, the endothelial cells play an important role in the homeostasis  
314 of renal plasma flow by synthetising vasoactive substances (nitric oxide, endothelin)[1]. Another important area is the  
315 juxtaglomerular apparatus. At the level of the afferent arterioles, this region contains granular cells that manufacture, store  
316 and release renin, which is involved in the formation of angiotensin (ANG) II and, as a last instance, in the release of  
317 aldosterone, playing a determining role in the regulation of the circulating volume and blood pressure[1].

**318 RENAL CLEARANCE**

319 In an effort to simplify the process of renal clearance, we can say that for substances that are not synthetised or metabolised  
320 by the kidneys, the only input to the kidney will be from the renal artery, and the only two outputs will be the renal vein and  
321 the ureter. This principle focusses on the excretion function into the urine in an amount of time (volume/time) and allows  
322 determination of the glomerular filtration rate (GFR) which, in other words, is the sum of the filtration function of all the  
323 nephrons in the kidney[1].

324 The dynamics of ultrafiltration at glomerulus are driven by Starling forces, pressure changes at this level will signify changes  
325 also in the GFR. Thus, a decrease in the resistance of the afferent arteriole will increase the pressure at the glomerular  
326 capillary and therefore the GFR. Contrary to this, a decrease in the resistance of the efferent arteriole will reduce the  
327 hydrostatic pressure at the glomerular capillary level, and, in addition, reduce the GFR [1].

328 **REGULATION OF RENAL BLOOD FLOW AND GLOMERULAR FILTRATION RATE**

329 The regulation of the blood flow that the kidneys receive, and the effectiveness of the glomerular filtration rate are essential to  
 330 maintain metabolic and electrolytic stability.

331 The stability of renal blood flow (RBF) and GFR could be affected by diverse pathways and regulated back to initial level by  
 332 endogenous counter-regulatory mechanisms.

333 Basicly, there are two mechanisms that plays a determinant role on RBF and GFR regulation: tubuloglomerular  
 334 feedback(TGF) and myogenic response. The TGF can alter the tone of the afferent arteriole by a pathway that involves  
 335 adenosine and/or ATP; in the other hand the myogenic response produces direct vasoconstriction of the afferent aretriole  
 336 based on the transmural pressure. Both mechanisms have the aim to stabilize renal function and protect the kidney from  
 337 hypertensive injury[3].

338 Within this autoregulation mechanism there would be some modulators that play an important role in the success of the  
 339 process, among them the most important ones are:

- 340 • **Sympathetic nerves**: when the external fluid volume falls, the sympathetic nerves release norepinephrine and  
 341 epinephrine, which causes vasoconstriction by union at the level of the afferent arteriole causing reduction of the  
 342 RBF and GFR[1].
- 343 • **Nitric oxide** (NO): the increase in the blood flow could determine the release of NO, which causes vasodilatation of  
 344 the afferent and efferent arterioles in the kidney[1].
- 345 • **Bradykinin**: its vasodilatory actions are explained by the release of NO and prostaglandins, increasing RBF and  
 346 GFR[1].
- 347 • **Prostaglandins** : in response to situations of ischemia or vasoconstriction ( for example after binding of ANGII at  
 348 the afferent and efferent arteriole) the kidney has the ability to produce prostaglandins (PGE<sub>2</sub> and PGF<sub>2α</sub>) that will  
 349 contribute to vasodilate the preglomerular vessels contributing in that way to increase or maintain the blood flow and  
 350 GFR[4-6]
- 351 • **Natriuretic peptides** (NPs): released by the atria and the ventricle (atrial natriuretic peptide (ANP) and brain  
 352 natriuretic peptide (BNP), these compounds have a vast number of receptors at the kidney level.

The interaction of these compounds with the receptor Natriuretic Peptide Receptor A (NPRA) generates, among others, the paradoxical effect of dilate the afferent arteriole and constrict the efferent arteriole, producing an increase in GFR[1].

**Angiotensin II:** Ang II is determinant in the regulation of the vascular resistance, GFR and tubular reabsorption at kidney level.

The efferent arteriole is more sensitive to ANG, and at low concentrations, ANG causes vasoconstriction of the efferent arteriole. Thus, this action causes an increase in GFR. At higher concentrations and due to the capacity to act in both afferent and efferent arterioles, the administration of ANGII produces an opposite mechanism decreasing the RBF, GFR and increasing the filtration fraction[1, 6, 7].

On the other hand mechanisms that intend to block ANG II generates an increase in RBF and pressure related changes in GFR [7].

## **INTRODUCTION TO KIDNEY CANCER AND PARTIAL NEPHRECTOMY WITH THE USE OF WARM ISCHEMIA**

### **EPIDEMIOLOGY**

There are basically two types of kidney cancer :

1. Urothelial (15-20%)
2. Renal cell carcinoma (70-80 %)

The remaining types are Wilms tumour (children 4-6%), lymphoma, sarcoma, and metastasis[8].

Renal cell carcinoma (RCC) is the most common solid kidney tumour[8], worldwide it is estimated that RCC accounts for almost 3% of all cancers, with a clear disposition for western countries, and a predominance of 1.5:1 of men over woman and a higher incidence and diagnosis in elderly population (>75 years of age)[8, 9].

The incidence is increasing due to the more frequent use of imaging studies such as ultrasound, computed tomography (CT)-scanning or magnetic resonance image (MRI)[8-10]. Therefore, the average diameter of the tumors has decreased over the last decades from 12 cm to 5.5 cm, and the total number of small renal masses (SRM) (2-4 cm) has increased[9, 10]. It is estimated that around 300.000 patients are diagnosed every year of kidney cancer worldwide[9].

378 Even though the incidence remains with a stable growth over the years, is it to note that the rates of mortality due to renal  
379 cancer in most of Europe, United States and Australia are in continuous decrease since 1990[8, 9]. This trend could be  
380 explained because the diagnosis is made in early stages of the cancer, but also due to a change of life habits, such as  
381 decreased smoke rates, better treatment options, and better access to the health system[9].

382 In Denmark around 1000 new RCC are diagnosed every year, responding also to 2-3% of all the newly diagnosed cancers. It  
383 is shown, as in the rest of the world, an increase in incidence from 12,8/100000 to 16,8/100000 habitants when the registries  
384 from the period 2011-2012 are compared with the period from 2017-2018[11].

385

## 386 **ETIOLOGY**

387 High body mass index (BMI), smoking, and hypertension are risk factors linked to RCC[8, 9, 11]. In addition, end stage  
388 kidney disease (ESKD), with the concomitant use of dialysis, represents a risk factor based on the chronic changes that the  
389 disease produces on the renal system[8]. Recent studies were able to find a correlation between diabetes and RCC,  
390 representing a matter of public health concern due to continuous increase of diabetes in the population[12].

391 Some genetic conditions predispose to the development of RCC e.g. Von Hippel-Lindau (VHL), hereditary papillary renal  
392 carcinoma, Birt-Hogg-Dube, hereditary leiomiomatosis, succinate dehydrogenase deficiency RCC, tuberous sclerosis, and  
393 PTEN hamartoma tumor syndrome (Cowden syndrome)[9]. Most of these syndromes are associated with the diagnosis of  
394 tumors in other parts of the human body[9]. There is no strong correlation between RCC and chemical exposure, with the  
395 exception to chlorinated solvents and asbest[9].

396 It is shown that moderate alcohol consumption, and a diet rich in fruit and vegetables, plus regular physical activity has a  
397 protective effect[8, 9, 11].

## 398 **TYPES OF RCC**

399 Based on the classification of the World Health Organization (2016) the most frequent kidney cancers are: clear cell renal  
400 carcinoma (ccRCC), papillary RCC, and Chromophobe RCC[8, 9, 11, 13]

401 Clear cell carcinoma is by far the most frequent type, representing 65-70% of all RCC, papillary tumors represents around 10-  
402 20%, and chromophobe only 5-7% of newly diagnosed RCC[11].

**403 BIOLOGY AND GENETICS OF KIDNEY CANCER**

404 The discovery of different genetic pathways in the last decades helped to understand the biology, development, and behavior  
405 of many cancers. With particular interest in kidney cancer, it has been of enormous interest to understand the VHL-HIF  
406 (hypoxia inducible factor)[14]. Under normal conditions the VHL gene has, among others, to trigger the degradation of HIF  
407 by the activation of different enzymatic processes. Malfunction of the VHL gene lead to overaccumulation of HIF and  
408 subsequent activation of HIF targets such as VEGF 1 (Vascular Endothelial Growth Factor) and PDGF (Platelet-Derived  
409 Growth Factor) resulting in uncontrolled growth, increased neovascularity, survival, and development of several cancer  
410 hallmarks[14].

411 The understanding of the VHL-HIF pathway allowed the comprehension of renal cancer as an entity which could be triggered  
412 by different genetic malfunctions. In the last decades the genes responsible for hereditary papillary renal carcinoma (HPRC),  
413 Birt-Hogg Dube, BAP1-tumor predisposition syndrome, Microphthalmia Transcription Factor (MiTF) family translocation  
414 renal cell carcinoma, familial mixed epithelial and stromal tumor (MEST) were all described[14].This allowed a more  
415 personalized treatment for hereditary conditions that may not fit in the general algorithms of diagnostic, treatment and follow  
416 up of kidney cancer.

417

**418 SYMPTOMS AND DIAGNOSIS**

419 The classical triad of hematuria, upper flank pain and abdominal mass described in some textbooks is infrequent. This  
420 combination is only present in less than 5% of the newly diagnosed RCC, and represents most of the times an advanced stage  
421 of RCC[9].The implementation of CT and MRI for multiple diseases has increased considerably the number of incidental  
422 diagnosis of kidney tumors, of those, the vast majority in early and asymptomatic stages and with diameter of less than 4  
423 cm[8-11]. Obviously, none of the abovementioned imaging diagnosis method can with a certainty of 100% demonstrate if the  
424 renal mass is either malign or benign. In the last decades consensus about IV (intra venous) contrast uptake and image  
425 characteristics has been done with the aim to increase the accuracy of the diagnose of RCC and avoid unnecessary surgery.  
426 Usually the renal masses will enhance more than 15-20 Hounsfield units (HU) without fat density should be consider highly  
427 suspicious of RCC[9]. In order to provide more information, the tumor biopsy has, in the last years, gained an important role  
428 in the diagnosis of small renal masses, and in some urological departments it has become the gold standard in the path to  
429 guide the patient for further treatment[9, 15].

430 **CLASSIFICATION**

431 It is based on the Tumor Node Metastasis classification system (TNM)[16].

432 Which evaluates the size of the tumor in cm (T1, T2, T3, T4), the presence of positive lymph nodes (N0, N1) , and metastasis  
433 (M0, M1) at the moment of diagnosis.

434 **TREATMENT**

435 After an MDT (multidisciplinary conference) where the individual case is presented and discussed a treatment is decided and  
436 later presented to the patient and relatives.

437 The treatment for RCC it is based in 4 modalities:

438 **1) ACTIVE SURVEILLANCE (AS):** is a method to follow an incidental renal mass between 2 cm and 4 cm .

439 It requires, as all the AS protocols, a close follow up with the use of images and biopsies, a clear definition of when  
440 to change to active intervention and the assumption, by the patient and the doctor, of a risk of evolution into a more  
441 aggressive cancer and the possibility of metastasis. Normally, the AS protocol is used in elderly patients with  
442 comorbidities, where the risk of a surgical intervention, per se, is higher than the risk of progression[9]. Active  
443 surveillance should be only offered if an eventual progression would be treated.

444  
445 **2) NEPHRON-SPARING** treatment could be either partial nephrectomy or ablation therapy.

446 **A) PARTIAL NEPHRECTOMY (PN):** it consists in the removal of the tumor and only a minor portion of  
447 healthy tissue to ensure safe margins[8, 17]. The first partial nephrectomy with oncological purposes dates from 1921  
448 and it was performed by Rosenstein[18]. The way to gain acceptance in the medical community was slow, and the  
449 consolidation of the technique waited until the publications of Licht and Novick in 1993[18-20]. They were able to  
450 demonstrate good results concerning oncological outcomes, peri postoperative complications, and mortality rates in  
451 241 patients with tumors of mean size of 3,5 cm[18-20]. Normally it requires to clamp the renal artery and vein for a  
452 suggested period of less than 30 minutes in order to allow the surgeon to work in a dry space to safely remove the  
453 tumor[21]. Nowadays for the treatment of certain tumors, with for example favorable locations, some surgeons have  
454 developed techniques that avoid the clamping of the artery or perform super-selective clamping of the branch or  
455 branches of the renal artery that supplies blood into the tumor location[21].

456 Overall , partial nephrectomy represents an improved way to save kidney functionality in patients with a non-  
457 optimal kidney function, and so, a probable way to avoid the serious complications that renal insufficiency could  
458 carry.

459 Partial nephrectomy is a challenging technique and is not exempt of complications, which can be divided in  
460 intraoperative and postoperative .

461 Among the first ones, the most common are bleeding, pleural or surrounding organ injuries and tumor violation[22].

462 The most common postoperative complications are: bleeding, pseudo aneurism, urine leakage, pneumothorax and  
463 renal failure[22].

464 To achieve the postoperative trifecta of negative margins, no urological complications and maintenance of 90% of  
465 the preoperative renal function there are non-modifiable and modifiable factors. Within the last ones it seems that the  
466 duration and clamp of the renal artery and vein plays a determinant role, because the clamp of these structures lead to  
467 a period of temporary ischemia of the nephrons[22, 23].

468 During the period of warm ischemia, a process of cellular suffering under norm thermic conditions begins[24]. The  
469 mechanism of cellular injury occurs at vascular level, where vasoconstriction and inflammation play a determinant  
470 role. There is mobilization of proinflammatory components such as interleukins, neurohumoral activation of  
471 angiotensin II and release of free oxygen radical, giving to the process the characteristic of a vicious cycle named as  
472 *ischemia- reperfusion syndrome*[23, 25].

473 The syndrome could occur in all the organs who experience sudden blockage of the irrigation for some minutes, but  
474 then is reestablish. With focus on the kidney, several studies arrived to the conclusion that human kidneys could  
475 tolerate no more than 30 minutes of warm ischemia at 37 C. Keeping the insult below 30 minutes, only acute tubular  
476 necrosis with slow but predictable recovery ( 3-4 weeks) is expected[24, 26, 27]. Situations that require between 30  
477 and 60 minutes of warm ischemia often results in severe injuries, with no reversible loss of function and elevated  
478 mortality[24, 27]. Moreover, preclinical studies with rats as subjects of study demonstrated that more than 90  
479 minutes of ischemia in the kidneys will result in a complete loss of function of the kidney with mortality rates of  
480 more than 80 %[24, 27].

481 In addition to the ischemia-reperfusion syndrome, the patients undergoing partial nephrectomy, and the patients  
482 exposed to other types of major surgery, such as major intrabdominal or intrathoracic surgery, are in serious risk to  
483 develop acute kidney injury (AKI) with an abrupt decrease in GFR[10].

484 Acute kidney injury is defined by the RIFLE score (risk-injury-failure-loss-end stage) as a reduction => than 25% in  
485 baseline eGFR (estimated glomerular filtrate rate) or >1.5-fold increase in baseline creatinine at discharge from  
486 hospital[28]

487 Specifically, postoperatively AKI is a common complication in patients with background of cardiovascular disease.  
488 Among them the risk of AKI varies in a proportion between 15- 35%, addressing hypovolemia, loss of perfusion  
489 pressure and hemodilution as main causes[10, 29, 30].

490 In patients undergoing partial nephrectomy the risk of AKI should not be underestimated as 20% of the patients will  
491 suffer this complication after the procedure[28].Several reports remark that the duration in days of AKI would play a  
492 determinant role in de development of CKD or worsening of the preoperative stage. Those patients with AKI for  
493 more than three days had a lower probability to recover 90% of the preoperative eGFR and had 6 fold risk to upstage  
494 CKD in comparison with those without postoperative AKI[28].

495 The link between temporary ischemia of the kidney and the development of postoperative AKI is consistent,  
496 showing that more than 20 minutes of warm or 35 minutes of cold ischemia increased the risk of AKI (24.4% vs.  
497 6.4% and 32.0% vs. 13.0%, respectively)[31]. In the same direction Lane and Simmons et al. associated that the risk  
498 of AKI increases 1% per minute of ischemia and decreases with the percentage of kidney tissue preserved.[14, 32].

499 Acute kidney injury is often followed by inflammation, with infiltration of neutrophil granulocytes and macrophages  
500 at renal level. In addition, there is a release of cytokines that accelerate the process of kidney damage[10, 33]. This  
501 population is therefore in a higher need for temporary use of hemodialysis, which increases the risk of postoperative  
502 mortality in more than 50%.and elevates also the risk to develop chronic kidney disease (CKD) and subsequently  
503 end stage kidney disease[10, 29, 30, 34].

504 Ischemia time also plays a determinant role in death donor kidney transplants; it has been noted that the success rate  
505 of the intervention has a strong relationship with the cold ischemia time from ablation to transplantation[35, 36].The  
506 outcomes concerning renal function and rate of rejection are considerably better when cold ischemia time remains  
507 below 12 hours[35, 36].

508 **B) THERMAL ABLATION:** it consists in the application of different sources of energy are used to achieve  
509 cellular death of the tumor by different techniques: open surgery, laparoscopic or percutaneous. It is reserved for  
510 tumors of less than 4 cm. The techniques most used are cryoablation and radiofrequency (RFA). It is shown that they  
511 could be effective for tumors of less than 4 cm compared with the oncological and functional outcomes of partial and  
512 radical nephrectomy (PN, RN ), but the benefits decrease dramatically when compared with tumors between 4 and 7  
513 cm[8, 9, 37]. However, there is no sufficient data to recommend these techniques as standard of care, and they



514 should only be offered when radical or partial nephrectomy are not an option due to the patient e.g. comorbidity, age,  
 515 poly pharmacy or a solitary kidney[8, 9, 11].

516 **3) RADICAL NEPHRECTOMY (RN):** the first described radical nephrectomy to treat a tumor was  
 517 performed by Langenbuch in 1875, but it was in 1903 that Gregoire reported the “en bloc” resection of the tumors as  
 518 we know nowadays[18]. The procedure could be performed by different approaches such as open surgery,  
 519 laparoscopic or robot assisted. The cancer specific survival after RN is outstanding, and the rate of postoperative  
 520 complications seems to be better when compared with PN; but in order to preserve as much renal function as  
 521 possible, RN is nowadays a technique, which has been relegated to the tumors that cannot be removed by partial  
 522 nephrectomy, commonly those of more than 7cm or the tumors located in close relationship with the renal hilum[8,  
 523 9, 11, 38].

524  
 525 **4) CYTOREDUCTIVE NEPHRECTOMY(CN):** from all newly diagnosed patients with RCC, 20% will  
 526 present metastasis at the moment of diagnosis[39, 40]. In this scenario, the standard of care for patients with good  
 527 performance status has been CN with concomitant oncological medical treatment[40]. The CN improves overall  
 528 survival in metastatic RCC, and helps to control symptoms derived from the disease, such as hematuria, flank pain  
 529 and paraneoplastic syndrome[40, 41] .

530  
 531 **ADAPTIVE CHANGES FOLLOWING PARTIAL OR TOTAL NEPHRECTOMY**

532 Following total unilateral nephrectomy (TN) or PN, the contralateral kidney/remaining kidney mass undergoes adaptive  
 533 changes. This phenomenon is well known and was first reported in 1672, when Roomhuysen, Zambecarius and Blanchard,  
 534 among others, discovered that a dog, in which TN was performed, could live with only one kidney without any problem. In  
 535 addition, they noticed that the remaining organ went through a compensative hypertrophy process.[19, 42, 43].

536 The process of compensatory kidney hypertrophy can occur after tumour resection with PN or TN and has also been observed  
 537 after elective nephrectomy in healthy kidney donors. Most studies conclude that the adaptive phase of the contralateral kidney  
 538 starts some hours following the surgery[44]. After one year, the remnant kidney may have achieved around 70% of the  
 539 aggregate function of two fully functional kidneys and may be able to keep levels of plasma creatinine and GFR at normal  
 540 levels[43-45].

541 We still await firm scientific evidence or causality of how the process of compensatory hypertrophy begins but several factors  
542 modulate or affect the mechanism, such as age, gender and pre-operative GFR.

543 Young male patients with better preoperative GFR respond better than other patients to the adaptive changes following total  
544 nephrectomy. In young male patients, the contralateral kidney could undergo compensatory hypertrophy, increasing its  
545 volume up to 39%[43, 44, 46-50]. In patients undergoing PN, as expected, the adaptive changes are of lesser magnitude but  
546 still present. They may experience hypertrophy in the contralateral kidney of around 9% after the first year of surgery[44].  
547 This discrepancy in the relative extent of hypertrophy may be explained by the simple fact that that in PN as opposed to total  
548 nephrectomy, less parenchyma is excised, and the hypertrophy stimulus is perhaps only temporal.

549 Hence, postoperative changes may be linked to the size of the tumour and the extent to which overall kidney volume is lost  
550 [43, 50-53].

551 Compensatory hypertrophy and GFR changes are important to avoid ESKD. Indeed, patients who experienced no  
552 compensatory changes have been reported to be at higher risk of developing CKD than patients who develop compensatory  
553 hypertrophy[46]. A similar effect has been observed in live healthy kidney donors; and those who had no early compensatory  
554 hypertrophy and GFR changes within the first month of surgery had a tenfold higher risk of developing cardiovascular and  
555 CKD than the general population[54-56].

556 At the humoral level, certain changes induced by surgery may help explain the mechanism of post-operative compensatory  
557 hypertrophy. Thus, levels of circulating of nitric oxide are elevated following nephrectomy[51]. In experimental studies it has  
558 been demonstrated that the implication of a circulating factor could be implied in the post operatory compensatory kidney  
559 hypertrophy after total nephrectomy, and blood transfusion of nephrectomised rats induced changes in GFR of healthy  
560 recipients[57]. Moreover the incubation of atrial natriuretic peptide and epidermal growth factor was effective to induce cell  
561 hypertrophy at the proximal renal tube during compensatory kidney growth[58].

562 In humans it has been noted that after TN, patients experience a significant increase in N-terminal pro-hormone brain NP  
563 (NT-proBNP). A similar mechanism occurs with mid-regional pro-hormone atrial NP (MR-proANP), remaining this  
564 particular peptide significantly increased after one year of surgery, probably supporting the role of natriuretic peptides in the  
565 mechanism of renal adaptation[43, 57].

566

**567 Natriuretic peptides**

568 The group of NPs (natriuretic peptides) consists of three structurally interrelated vasoactive peptides with a molecular weight  
569 below 10 kDa. They are known as ANP, B-type NP (BNP) and C-type NP (CNP)[10, 59-61].

570 NPs are synthesised, stored and secreted at the level of myocytes[62]. Their main functions are to promote water and  
571 sodium excretion, but also to increase RBF, lower blood pressure and suppress renin and aldosterone secretion and increase  
572 lipolysis[10].

573 The expression of the NP receptors is widespread in the body. Hence, NP receptors are plentiful in the myocardium, brain,  
574 endothelial and smooth muscle of vessels, adipocytes, kidney epithelium and glomerular podocytes[10, 63-66]. In the human  
575 kidney, NPR-A expression was observed in the outer medulla and the pericytes and endothelial cells of the descending vasa  
576 recta[10, 67]. NPR-C was also abundantly expressed in the kidney as opposed to NPR-B which was not found in the  
577 kidney[10, 67].

578 After ligand binding with NPR-A, guanylyl cyclase is activated and a concomitant rise of cyclic guanosine monophosphate  
579 (cGMP) is observed[10, 68-70]. Thus, in preclinical studies in mice, genetic deletion of NPR-A resulted in hypertension,  
580 hypervolemia, cardiac hypertrophy, fibrosis, and impaired salt excretion[10, 71].

581 A different mechanism is seen after ligand binding by NPR-C. Thus, ligand binding by NPR-C internalises the receptor-  
582 ligand complex and takes the NP out of circulation, facilitating its degradation[10, 72, 73]. In addition to the mechanism of  
583 degradation by NPR-C, the NPs are also degraded by the neutral endopeptidase neprilysin (NEP) and excreted by glomerular  
584 filtration in approximately 5 minutes[10, 72]. The mechanism of inactivation of NPs by NPR-C or neprilysin sparked the  
585 hypothesis that catabolic degradation inhibition may increase circulating level of peptides and hence exploit their beneficial  
586 effects[10].

587

**588 EFFECTS ON SODIUM/VOLUME REGULATION AND BLOOD PRESSURE OF NATRIURETIC PEPTIDES**

589 The average half-life of circulating NP is around 5 minutes. Based on that feature several studies investigated the effects of  
590 ANP or BNP by continuous infusion, showing a reduction of mean arterial pressure (MAP) of around 30 mmHg[10, 74].  
591 Even after administration of ANG II, which stimulates the concentration of aldosterone, ANP attenuated the hypertensive  
592 effect[10, 75].

593 In terms of sodium/volume regulation, no direct relation seems to exist between the dose of ANP and its effect, indicating that  
594 the effect may not occur after receptor interaction. In fact, no expression of NPR-A at tubular level was observed[76]. A  
595 probable explanation for this is that sodium handling could be indirectly affected by sympathetic nerve activity and inhibition  
596 of the renin-aldosterone-angiotensin-system (RAAS)[10, 67, 77].

597

#### 598 **EFFECTS OF NATRIURETIC PEPTIDES AT KIDNEY LEVEL.**

599 Mechanism that could enhance oxygen supply, blood flow and maintain or increase GFR could be of vital importance to  
600 avoid or antagonize threatening AKI, which is a common diagnosis among severely ill patients and/or patients having  
601 undergone major surgery[10, 29, 30].

602 Accordingly, infusion of ANP above physiological levels could induce vasodilatation of vasa recta and constrict efferent  
603 arterioles maintaining GFR[10, 78-80].

604 In addition to the maintenance of oxygen supply at the medullary level, ANP infusion could led to an increase of GFR and  
605 diuresis, but with a stable filtration fraction and RBF[10, 81-83].

606 The continuous infusion of atrial natriuretic peptide was effective to increase GFR and sodium extraction after total  
607 nephrectomy in rats[84]. Expression of the natriuretic receptors at the kidney level under this conditions was not  
608 overexpressed at the papilla, medulla or cortex but the infusion of the ANP lead to increases of GFR and FeNA greater than  
609 in controls[84]

610 The ability of natriuretic peptides to increase or maintain the GFR but without increasing the filtration fraction could be  
611 interpreted as of vital importance during AKI scenarios because that will imply a stable consumption of O<sub>2</sub> which is critical  
612 specially for delicate areas of the organ as the renal medulla. [10, 85, 86].

613

614

615

616 **ANIMAL MODELS TO EVALUATE KIDNEY FUNCTION**

617 The most used animal models to evaluate kidney function and kidney disease are rodents. Such models represent a convenient  
618 option to conduct research but has the disadvantage that does not reproduce the human kidney anatomy and function in an  
619 accurate way and therefore the results of the investigations could be difficult to translate to the human field.

620 Pigs represent an opportunity to study the effects in vivo in a large animal setting. The use of a model that is similar to the  
621 human anatomy and function allows to practice surgeries, blood- and urine test determinations in similar ways as in  
622 patients[87].

623 Pigs were chosen in the present study for several reasons: Pharmacodynamic and -kinetic aspects; the possibility to do precise  
624 kidney tissue reduction; the ability to perform separate timed collections of urine from ureters and thus each kidney; the  
625 possibility to apply same methods of precise GFR determination by tracer methods and finally a metabolism similar to  
626 humans.

627 The investigations at the research institute of Aarhus University Hospital served as a basis to inspire our approach. In their  
628 studies of kidney donation and effects of kidney ischemia in pigs they were able to demonstrate the feasibility of the methods  
629 and the reproducibility of the technique of measurement of GFR using  $^{51}\text{Cr}$  EDTA as radiotracer. Another important  
630 consideration is these investigations is to address the resistance to ischemic injury that the pigs have[87, 88]. Therefore, we  
631 decided to adopt a similar experimental strategy and use 1h ischemia time by clamping of the renal artery and vein to  
632 investigate if the treatment with Entresto<sup>®</sup> for a period of 15 days could play a protective role at the kidney level in the  
633 immediate postoperative phase.

634 The use of natriuretic peptides or the inhibition of their degradation has been extensively used with rodents as animal model.  
635 The results of these studies showed that the natriuretic peptide pathway could have substantial implications in the  
636 maintenance of GFR and fractional excretion of Na after total nephrectomy, but as explained above this model could  
637 represent a lack of transferability to a clinical setting. [58, 84].

638 The use of a model with a similar kidney structure and function could help us to address the answer of the role that Entresto<sup>®</sup>  
639 or similar drugs could play in kidney protection after the addition of another detrimental factor represented by the ischemia-  
640 reperfusion scenario after partial nephrectomy and prolonged warm ischemia.

641

642 **HYPOTHESIS AND AIMS:**

643 The endogenous postoperative increase of natriuretic peptide levels could relate to the magnitude of compensatory  
644 postoperative hypertrophy of the kidney and its increase in single kidney GFR after total nephrectomies. We speculate that  
645 the natriuretic peptide pathway may also have a role in the maintenance of kidney function after partial or total nephrectomy.  
646 Therefore, approaches to prolong the half-life of the peptides would be beneficial.

647 To address these proposals, a series of hypotheses were postulated:

648 Overall, we hypothesize that the treatment with a pharmacologic drug to enhance in vivo the half-life of NPs by LCZ696  
649 before, during and after elective kidney mass reduction by partial nephrectomy using an animal model will contribute to:

- 650 1) maintain preoperative levels of total and single kidney GFR.
- 651 2) reduce post operative glomerular barrier injury measured as proteinuria and tissue injury, and
- 652 3) increase ANP/BNP plasma concentrations more than sham.

653

654 We also hypothesize that constant elevations of natriuretic peptides could play a potential role on postoperative kidney  
655 hypertrophy after total or partial nephrectomy.

656

657 **Aims:**

658 **a.1** To perform an invited review to obtain an overview of the Natriuretic peptide pathway and elucidate the effects that they  
659 might have in kidney function. We aimed to determine the protective effect of the use of NPs and ANG-renin-neprilysin-  
660 inhibitors (ARNI) drugs at kidney level, in different pathological scenarios such as ischemia reperfusion syndrome, major  
661 cardiovascular and thoracic surgeries, acute kidney injury and chronic kidney disease.

662 **a.2A** To determine the feasibility of a single kidney GFR measurement using  $^{99m}\text{TC}$ -DPTA as a radiotracer by ureter  
663 sampling of urine in a pilot study, using pigs as an animal model and

664 **a.2B** to perform a randomised placebo-controlled open-label pre-clinical study investigating the protective action of LCZ696  
665 at kidney level after laparoscopic PN with prolonged ischemia time.

666 **a.3** To elucidate the role of NPs in the mechanism of postoperative kidney hypertrophy after PN or TN.

667

668 **ANIMAL LEGISLATION AND ETHICS**

669

670 The study was approved by the Board of Animal Experiments, the Danish Animal Experiments Inspectorate under the  
671 national Ministry of Environment and Food (license 2018-15-0201-01576).

672 Before, during and after the operative procedures, the pigs were housed at the Biomedical Laboratory at Aalborg University  
673 Hospital, in accordance with national guidelines regarding the care and use of laboratory animals.

674 All interventions were conducted under general anaesthesia using the same protocol for all groups. In the postoperative  
675 period, the animals were given analgesics on the first day as planned and analgesics were continued if needed. The animals  
676 were controlled daily; and if unforeseen events occurred per-/postoperatively and the three stress criteria - pain, suffering or  
677 discomfort - could not be controlled, they were scheduled for euthanasia with a lethal dose of intravenous phenobarbital.

678

679

680

681

682

683

684

685

686

687

688

689 **MATERIAL AND METHODS**

690 **STUDY 1**

691 To elucidate the potential protective effect of the use of NPs after kidney level in different pathological scenarios such as  
 692 ischemia-reperfusion syndrome, major surgeries, acute kidney injury and chronic kidney disease, an invited review was  
 693 performed.

694 The review was entitled “Protection of kidney function and tissue integrity by pharmacologic use of NPs and neprilysin  
 695 inhibitors”[10].

696 Four main investigators conducted a systematic search. The search terms were ((((((natriuretic peptides) OR Entresto) OR  
 697 sacubitril) OR valsartan) OR chronic kidney disease) OR acute kidney injury) OR ischemia reperfusion syndrome. We  
 698 included articles in English describing investigations performed in preclinical or clinical setting[10].

699

700

701

702

703

704

705

706

707

708

709

710



711 **STUDY 2**

712 Due to the lack of information about methods with which to measure single kidney GFR in pigs using  $^{99m}\text{Tc}$ -DPTA as a  
713 radiotracer, we performed an initial pilot study.

714 A total of six female pigs with a mean weight of 32 kg (27-38) were enrolled to 1) determine the reproducibility of repetitious  
715 GFR measurement, 2) make a comparison of plasma decay-based vs bladder-collection-based GFR determination and 3) at  
716 termination, appraise the feasibility of measurement of single kidney GFR using  $^{99m}\text{Tc}$ -DPTA in a pig model (CONSORT  
717 diagram) (Fig. 1).

718 For the procedures, general anaesthesia was induced using zoletid 150 mg/10 kg body mass as pre-anaesthetic induction  
719 followed by continuous infusion of fentanyl 8.5  $\mu\text{g}/\text{kg}/\text{hr}$  and propofol 2mg/kg/hr to maintain enough depth of anaesthesia.  
720 Continuous measurements of blood pressure, oxygen saturation, respiratory curves, temperature and heart rate were  
721 conducted during the procedures[89].

722 **GFR determination in pigs:** Ten million Becquerels (MBq) of  $^{99m}\text{Tc}$  diethylenetriaminepentaacetic acid (DTPA) were  
723 given as a bolus injection in a peripheral venous catheter, and blood samples were collected, using a central venous catheter,  
724 at different time points (5, 10, 15, 30, 45, 60, 90, 120, 150, 180, 210 and 240 minutes) after injection. At baseline, the  
725 complete amount of urine was collected from the bladder using a 10-French (Fr.) Foley silicone catheter. After 15 days,  
726 plasma and single-kidney GFR determinations were again performed. For determination of single-kidney GFR, a 5 Fr.  
727 catheter was inserted into each ureter, placed and fixed in the renal pelvis to allow collection of urine during 4 hours[89].

728 Blood samples and a sample of the collected urine were counted in a Wizard2 2480 gamma counter (PerkinElmer, Mass.,  
729 US), and the plasma concentration curve was determined as a bi-exponential fitting to the plasma data. The GFR was  
730 calculated by the principle that clearance (GFR) equals excreted activity divided by the corresponding area under the curve  
731 (AUC) for the plasma concentration curve[90, 91]. From the fitted curve, the AUC can easily be calculated, either for a  
732 specific time interval ( $\text{AUC}_{\text{urine}}$  = area from injection to end of urine collection) or until infinity ( $\text{AUC}_{\text{infinity}}$ ). Based on  
733 activity excretion from a single kidney,  $\text{Q}_{\text{urine-R}}$  or  $\text{Q}_{\text{urine-L}}$ , single-kidney renal function was calculated as  $\text{GFR}_{\text{urine}} =$   
734  $\text{Q}_{\text{urine}}/\text{AUC}_{\text{urine}}$ , with  $\text{Q}_{\text{urine}}$  for the relevant kidney. If time is stretched to infinity, all the injected tracer ( $\text{Q}_0$ ) will also  
735 have been excreted, giving the standard formula  $\text{GFR}_{\text{total}} = \text{Q}_0/\text{AUC}_{\text{infinity}}$ [89].

736 With the positive results about feasibility of measurement of GFR using  $^{99m}\text{Tc}$ -DPTA in pigs we followed to the phase 2 of  
737 the study that consisted in an experimental trial to test possible positive effects that the treatment with LCZ696 could have on

738 single kidney GFR, proteinuria and blood levels of natriuretic peptides after partial nephrectomy and prolonged ischemia time  
739 of 60 minutes.

740 Before initiation of the study, we made a power calculation to determine the minimum number of pigs to be enrolled in order  
741 to find a possible difference of around 10 ml in GFR between intervention and no intervention groups. We settled an alpha  
742 level of 0.05 and a power of 90 % giving us an estimation of a of 6 pigs per group. We decided to add a buffer of 2 pigs per  
743 group contemplating possible dropouts and in addition incorporate 8 pigs as control animals.

744 A total of 24 landrace female pigs with a mean weight of 32 kg (27-38) were enrolled and randomised into four groups (Fig.  
745 1). The randomization was blind to the main investigator. The animals were enrolled by pairs, and one day before the surgery  
746 the veterinarian staff choose one of the animals to start administrating the drug to avoid possible bias during the surgery. Only  
747 after the surgical procedure the main investigator discovered which animal was receiving LCZ696.

748

749

750

751

752

753

754

755

756

757

758

759

760 Groups:

761 1) Laparoscopic PN and treatment with Entresto® (LCZ696 49/51 mg/day) for 15 days, starting one day prior to the surgery (n  
762 = 8)

763 2) Laparoscopic PN and treatment with vehicle (n = 8)

764 3) Sham surgery and treatment with Entresto® 49/51mg/day for 15 days (n = 4)

765 4) Sham surgery and vehicle treatment (n = 4).




Figure 1 CONSORT diagram

**Description of the procedures**

766  
767 Baseline GFR was measured prior to surgery under general anaesthesia, using the protocol mentioned previously. For the  
768 laparoscopic surgery groups, the anaesthetic protocol was slightly changed to ensure enough depth of anaesthesia during  
769 surgery. The pre-anaesthetic protocol included zoletid 1.5-2.0 mL/10 kg and continuous infusion of propofol 3.3mg/kg/hour  
770 and fentanyl 13 µg/kg/hour. Central venous and arterial catheters were placed under ultrasound guidance; afterwards, the pigs  
771 were placed in upper right flank position. The skin of the pigs was prepared using chlorhexidine solution, and the surgical  
772 field was delimited using sterile single-use cloth. Once the operation area was ready, we proceed with installation of  
773 pneumoperitoneum using the Hansson open technique to minimise intrabdominal lesions; a pressure of 8 mmHg was settled  
774 as a standard. Two 10 mm ports and one 5 mm port were established to allow camera and instrument entrance, using the same  
775 port position as in human procedures[89].

776 Once the camera was in the abdominal cavity, the first step was to identify the kidney's pedicle (vein and artery),  
777 meticulously dissect the components and place a bulldog clamp to close the organ's irrigation; at this precise moment,  
778 measurement of the warm ischemia time began[89].

779 The right upper pole of the kidney was identified and excised. Following the procedure, the specimen was immediately  
780 removed, weighed, and divided into two sections. One piece was immersion fixed in 4% paraformaldehyde to allow further  
781 histological analysis; the other section was snap frozen in liquid nitrogen. The remaining kidney was sutured, and organ  
782 perfusion was stopped for a period of 60 minutes.

783 The length of the period of warm ischemia was based on the recommended kidney ischemia time in humans (below 30  
784 minutes)[28] and in the results of previous investigations in pigs evaluating the effect of ischemia-reperfusion for periods of  
785 around 120 minutes but without the additional insult of partial nephrectomy[87].

786 The bulldog clamp was then removed, perfusion was assured under visual inspection and haemostasis was controlled. As a  
787 last step, the instruments were removed under vision and pneumoperitoneum was evacuated to avoid postoperative pain. The  
788 muscular fascia was sutured with Vicryl 2.0 in a separate fashion to avoid postoperative hernias, and the skin was sutured  
789 using Vicryl 3.0 in an intracutaneous fashion. Local anaesthesia was administered at the fascia level of the surrounding area  
790 of port placements[89].

791 For the surgical procedures, two pigs were enrolled the same day and the investigator was blinded to which pig received  
792 Entresto® or vehicle prior to the laparoscopic PN of the right kidney with 60 minutes of ischemia[89].

793 After anaesthetic recovery, the pigs were housed in a stall for a period of two weeks. During this period, they had free access  
794 to water and were feed following the veterinarianian recommendations[89].

795 Non-steroid anti-inflammatory drugs (NSAIDs) were used only for the first postoperative day, and Amoxicillinum  
796 trihydricum 150/mL was used as a single preoperative dose of 1 mL/10 kg intramuscularly. No postoperative treatment was  
797 needed in any of the pigs. Administration of oral Entresto<sup>®</sup> 49/51mg/daily for 15 days, starting the day prior to surgery, was  
798 made possible using a small portion of apple given with the medicine. After two weeks, GFR was again measured. On this  
799 occasion, <sup>99m</sup>TC-DPTA clearance was performed separately for the right and left kidney. For that purpose, the ureters were  
800 isolated and clipped distally. Catheters with a size of 5 Fr. were inserted and placed in the renal pelvis, allowing collection of  
801 single kidney urine for 4 hours[89].

802 Afterwards, both kidneys were removed, and sections were frozen or fixed in 4% paraformaldehyde for future analyses. The  
803 pigs were then euthanised by using an overdose of 10 mL intravenous sodium pentobarbital 400 mg/dL[89].

#### 804 **Plasma and urine sample collection**

805 For plasma analysis, 10mL blood was drawn at three different time periods: baseline, after 2 hours of surgery and at  
806 termination. Blood was collected in two lithium-heparin coated tubes and centrifuged at 3,000 rpm for 10 min to obtain two  
807 tubes of 2 mL plasma for each time point. One sample from each time point was stored at -83 °C; the other was analysed for  
808 creatinine, Na<sup>+</sup>, K<sup>+</sup>, urea and albumin. Urine was sampled at the mentioned time points to measure Na<sup>+</sup>, K, albumin, total  
809 protein, urea and creatinine; and urine was measured continuously during the entire process to obtain data on urine flow[89].

#### 810 **Statistical analysis**

811 Normal distribution was assured by performing the Shapiro-Wilk test and then two-way analysis of variance (ANOVA) with  
812 95% confidence intervals (CIs) and post hoc analysis by Tukey's multiple comparison test. A  $p < 0.05$  was considered  
813 statistically significant. The differences between and within groups were analysed at baseline and after 15 days. For all the  
814 statistical analyses, the software of Prism Graph Pad 9<sup>TM</sup> was used[89].

#### 815 **Expected findings**

816 We hypothesized to find a difference in GFR, proteinuria and blood levels of natriuretic peptides between the groups with PN  
817 + LCZ696 vs PN + placebo.

818

819 **STUDY 3.**

820 The study was a post hoc study derived from an original study that was conducted from July 2016 to August 2019. In the  
821 original protocol a total of 74 participants were enrolled prior to partial or total nephrectomy at the departments of urology of  
822 Odense and Zealand University Hospital. The original study was approved by the Scientific Ethics Committee for the Region  
823 of Southern Denmark (S-20140044) and is registered at ClinicalTrials.gov, identifier: NCT02646293. After selection fifty-  
824 four patients were included in the original trial and assigned to either unilateral TN (n = 35) or PN (n = 19). Kidney function  
825 was assessed by both creatinine (Cr) ethylenediaminetetraacetate (EDTA) (Cr<sup>51</sup>-EDTA) and <sup>99m</sup>Tc-technetium (Tc)  
826 diethylenetriaminepentaacetic acid (DPTA) (<sup>99m</sup>Tc-DPTA) before surgery and 3 and 12 months after nephrectomy. Urine and  
827 plasma were collected at several time points: (I) pre-surgery, (II) 24 hours after surgery, (III) 5 days after surgery, (IV) 21  
828 days after surgery, and (V) 3 and (VI) 12 months after surgery. At these time points, levels of albumin and creatinine, NT-  
829 proBNP, MR-proANP and aldosterone were determined[43].

830 The functional distribution of the kidneys was assessed using preoperative renal scintigraphy. Additionally, the patients who  
831 received PN had two additional scintigraphies performed at 3 and 12 months after surgery. Estimation of single-kidney GFR  
832 was done by assessing the homogeneity of the distribution of kidney function and then dividing total GFR by two[43].

833 **Post hoc study: Volumetric analyses**

834 In the original cohort all the patients from Odense University Hospital diagnosed with RCC were independently controlled by  
835 CT scans before nephrectomy and one year after surgery. Thus this allowed us to conduct an observational study with a  
836 total of 19 patients of whom 8 underwent PN and 11 TN[43].

837 For all patients, preoperative CT scans were compared with the one-year postoperative images. The preoperative volume of  
838 the kidneys and tumour and the postoperative volume of the contralateral kidneys were assessed by using the image  
839 segmentation and three-dimensional (3D) reconstruction open-source software 3D Slicer[43, 92].

840 The patients who had been donors were excluded from the study as no postoperative CT scans were done as a default  
841 practice.

842 **Statistics**

843 All statistical analyses were performed in the GraphPad Prism software version 9. Datasets were analysed using the Shapiro-  
844 Wilk test to determine the Gaussian distribution followed by ANOVA with the Sidak *post hoc* analysis. Results were  
845 interpreted as significant if  $P < 0.05$ [43].

846

847 **Expected findings**

848 We hypothesized to find a persistent elevation of Natriuretic peptides blood levels at different timepoints after partial or total  
849 nephrectomy and a possible direct correlation between the magnitude of the kidney postoperative hypertrophy compensation  
850 and levels of Natriuretic peptides.

851 As secondary findings we wanted to document the role and correlation of preoperative GFR levels and magnitude of  
852 hypertrophy and the adaptative changes following total nephrectomy based on p-creatinine levels, albumin/creatinine ratio and  
853 single kidney GFR levels.

854

855

856

857

858

859

860

861

862

863

864

865

866


867 **RESULTS**

868 **STUDY 1**

869 The review provided an overview of the different types of NPs and the different actions at kidney level. The main results of  
 870 the systematic review were:

871 **Degradation of the Natriuretic peptides.**

872 The binding of NP with NPR-C triggers a mechanism which internalises the receptor-ligand complex, taking the NP out of  
 873 circulation and facilitating its degradation[10, 72, 73]. In addition to the mechanism of degradation by NPR-C, the NPs are  
 874 also degraded by NEP and excreted by glomerular filtration in approximately 5 minutes[10, 72]. The mechanism of  
 875 inactivation of NP's by NPR-C or neprilysin sparked the hypothesis that catabolic degradation inhibition may increase  
 876 circulating level of peptides and hence exploit their beneficial effect[10] (Figure 2).



877  
 878 *Figure 2 ANP receptors and degradation pathways*

879 **Combination of natriuretic peptides and furosemide.**

880 In patients undergoing uncomplicated heart surgery, furosemide increased renal blood flow and reduced filtration fraction  
 881 and renal oxygen demand. However, it also reduced GFR. Opposite to this, ANP without the use of furosemide seemed to



882 increase GFR, keep blood flow stable and could present an increase in filtration fraction and consequently oxygen demand  
883 when used at low doses[10, 93].

884 Studies showed [10, 30, 94, 95] that the combination of the two drugs may have an additive effect, resulting in increased GFR  
885 and RBF, decreased renal vascular resistance and unaffected filtration fraction.

886 A main outcome in patients who received the combination of NPs and furosemide was an increase in creatinine clearance and  
887 a reduced risk of dialysis and AKI[10, 30, 94, 95]

888

### 889 **Inhibition of neprilysin and its impact on the plasma concentration of natriuretic peptides.**

890 Different approaches have been used to increase the plasma concentration of NPs due to their short life. One simple but  
891 difficult way is to administer the peptides under continuous infusion; another innovative path is to focus on the degradation  
892 cascade. Since NPR-C inhibition does not correlate with considerable effects observed at the vascular level, several studies  
893 have targeted the inhibition of the NEP neprilysin, which drives NP degradation[10].

894 With a predilection of neprilysin for degradation ANP over BNP, it was shown that ANP can increase several folds during  
895 NEP inhibition[10, 96-101]. A major challenge is that neprilysin, beyond NPs, has several substances as substrates, such as  
896 endothelin, bradykinin, vasopressin, and ANG II. Therefore, their degradation could carry serious side effects. One well-  
897 described side effect is angioedema, which occurs after bradykinin degradation[10, 102].

898 To decrease the percentage of patients suffering from side effects after use of NEP inhibitors, new drugs were released to the  
899 market featuring a combination of NEP inhibition + ANG II inhibition, the so-called ARNIs, of which LCZ696 (Entresto<sup>®</sup>,  
900 Novartis Pharmaceuticals, Basel, Switzerland) has been commercially available since 2015.

901 In preclinical studies, use of ARNIs increased survival on rats with end-stage renal disease compared with valsartan alone[10,  
902 103] (Table 1). In addition, the combination of neprilysin inhibitors and enalapril or valsartan lowered proteinuria,  
903 glomerulosclerosis and tubulointerstitial fibrosis, increasing the production of nitric oxide compared with enalapril alone[10,  
904 103, 104].

### 905 **ARNI drugs and their effect in kidney warm-ischemia reperfusion models**

906 In pre-clinical kidney ischemia-reperfusion models, the groups not receiving ARNI drugs had higher levels of urea, creatinine  
907 and kidney injury markers than animals receiving ARNI drugs after reestablishment of circulation[105]. In addition, ARNI

908 treatment also had more anti-inflammatory and anti-fibrotic effects than angiotensin blockers only[10, 106].Thus, in Dahl-  
 909 salt-sensitive rats receiving Entresto®, the decline in GFR was mitigated and proteinuria mildly attenuated[10, 107] (Table 1).

910  
 911  
 912

| AUTOR           | YEAR/TYPE OF STUDY      | MODEL  | DRUG TESTED  | OUTCOMES  |
|-----------------|-------------------------|--|--|---|
| <b>Benigni</b>  | 2004/Randomized/20 rats | 5/6Nephrectomy                                     | Oral Vasopeptidase inhibitor vs Enalapril alone            | >GFR andrenal blood flow                              |
| <b>Chujo</b>    | 2010/Randomized/60 rats | 45min ischemia/reperfusion+ nephrectomy left right | IV Atrial NatriureticPeptide                               | >Outler medullary flow, decrease of plasma creatinine |
| <b>Jin</b>      | 2014/Randomized/24rats  | Unilateral Nephrectomy                             | IV C-type Natriuretic Peptide                              | Augmented expression of epidermal growth factor       |
| <b>Cao.</b>     | 2015 Randomized/36 rats | Ischemia/reperfusion                               | Iv Lyophilized recombinant human Brain Natriuretic Peptide | >GFR and renal blood flow                             |
| <b>Moriyama</b> | 2016 Randomized 18 rats | 30min bilateral Ischemia/reperfusion               | IV Atrial NatriureticPeptide                               | Reduction of NGAL marker level                        |
| <b>Ushijima</b> | 2017 Randomized/23rats  | Right nephrectomy+2/3left nephrectomy              | Oral LCZ696(Entresto) vs ANG TII Blockers                  | Delay In progression to ESKD                          |
| <b>Chen</b>     | 2017 Randomized/30 rats | Hypovolemic Shock                                  | IV C-type Natriuretic Peptide                              | >GFR andrenal blood flow                              |
| <b>Jing</b>     | 2017/Randomized/32 rats | 5/8Nephrectomy                                     | Oral LCZ696(Entresto) vs ANG TII Blockers                  | Lower levels of cellular hypoxia                      |
| <b>Kolsrud</b>  | 2020/Randomized/20pigs  | Cardiopulmonar By-pass                             | IV infusion of Atrial Natriuretic Peptide                  | >GFR without affection of renal oxygen delivery       |
| <b>Suematsu</b> | 2018 Randomized/34rats  | 5/6Nephrectomy                                     | Oral LCZ696(Entresto)                                      | Delay In progression to ESKD                          |

913  
 914  
 915

*Table 1 pre-clinical studies testing the effects at kidney level of NPs by infusion or Inhibition of degradation.*

916 **ARNI class drugs and their effects on kidney function and tissue protection in clinical studies.**

917 To date (August 2023), seven randomised clinical studies have been conducted in patients with CKD and hearth failure. The  
 918 conclusions of these studies on the effect of the use of ARNI are not completely aligned[102, 108-112]. The  
 919 PARAMOUNT[112] and the PARAGON HF [110] studies found that ARNI prevented a change in eGFR at 12 months and  
 920 reduced the percentage of patients who died due to ESKD[10, 110, 112]. Also, the IMPRESS and OVERTURE studies  
 921 reported beneficial effects after use of omapatrilat, but both studies had less statistical power than the PARAGON HF and the  
 922 PARAMOUNT study. They described a lower rate of renal impairment. However, the definition of renal impairment was not

923 published in IMPRESS and no *P* value was available in OVERTURE[102, 111]. In addition, lower rates of urea and  
 924 creatinine were found in patients treated with omapatrilat[10, 111].

925 The PARADIGM study was also able to demonstrate a slower decline in eGFR in patients receiving Entresto® than in patients  
 926 only receiving enalapril[10, 113].

927 Contrary to the positive results in the IMPRESS, PARAMOUNT, PARAGON, PARADIGM and OVERTURE studies, the  
 928 trials EVALUATE[108] and UK-HARP-III[109] were not able to detect differences in changes in eGFR or in the levels of  
 929 plasma urea or creatinine after follow-up[10, 108, 109] (Table 2 ).

930

| STUDY       | TYPE OF STUDY | MODEL                               | DRUG TESTED              | OUTCOMES                                      |
|-------------|---------------|-------------------------------------|--------------------------|---|
| PARAMOUNT   | Randomized    | Patients with heart failure and CKD | LCZ696 vs Valsartan      | < changes in eGFR and mortality due to ESKD   |
| PARAGON     | Randomized    | Patients with heart failure and CKD | LCZ696 vs Valsartan      | < changes in eGFR and mortality due to ESKD   |
| IMPRESS     | Randomized    | Patients with heart failure and CKD | Omapatrilat vs Enalapril | < renal impairment, blood urea and creatinine |
| OVERTURE    | Randomized    | Patients with heart failure and CKD | Omapatrilat vs Enalapril | < renal impairment, blood urea and creatinine |
| PARADIGM    | Randomized    | Patients with heart failure and CKD | LCZ696 VS Enalapril      | Slower decline in eGFR                        |
| EVALUATE    | Randomized    | Patients with heart failure and CKD | LCZ696 vs Valsartan      | similar eGFR and p-creatinine                 |
| UK-HARP III | Randomized    | Patients with heart failure and CKD | LCZ696 vs Irbesartan     | similar eGFR and p-creatinine                 |

931 *Table 2 Randomized Clinical Trials testing ARNI drugs*

932

933

934

935

936


937

938

939

940 **STUDY 2**

941 The first part of the study consisted of a pilot study where GFR was successfully estimated by plasma decay and from bladder  
 942 urine collected at study entry. Plasma decay curves of GFR were successfully determined and used to estimate GFR. The  
 943 average values of measured GFR were  $65 \pm 11$  mL/min (Fig 3). When GFR was measured by plasma clearance of  $^{99m}$ Tc-  
 944 DTPA through quantitative urine collection, the result was a mean of  $54 \pm 12$  mL/min (85% of plasma decay results  $P > 0.05$ )  
 945 when urine was collected from the bladder [89] (Fig.3). When urine was collected from each kidney the sum of single kidney  
 946 GFRs (25 mL/min from the right side and 31 mL/min from the left side, SE 2.38) matched the value obtained by bladder  
 947 urine collection ( $56 \pm 14$  mL/min) and was not significantly different from plasma decay measurements ( $P = 0.72$ ) in any of  
 948 the groups [89] (Figure 3). After completion of the pilot study, we continued with the randomized preclinical trial to  
 949 determine the effect that LCZ696 could have in kidney function after partial nephrectomy and extended ischemia time.



956 *Figure 3 Diagram shows data from the initial pilot series with measured GFR using*  
 957  *$^{99m}$ Tc-DTPA by the plasma decay approach and by urinary clearance at baseline and*  
 958 *15 days after PN. The values obtained by the sum of single-kidney clearances were not*  
 959 *statistically different from the values obtained by the plasma decay method.*

960 **Baseline parameters in pigs subjected to sham or partial nephrectomy.**

961 The pigs included in the intervention trial had a mean entry weight of 32 kg (27-38); MAP, O<sub>2</sub> saturation and heart rate at  
 962 baseline were  $94 \pm \text{mmHg}$ , 78 bpm and 99%, respectively. No differences between groups at baseline or after 15 days were  
 963 noted (Table 3). Grams and percentage of tissue removed during PN were on average the same in the two groups (Entresto®  
 964 or vehicle,  $P = 0.85$ , corresponding to a mean of  $21 \pm 4$  gr and 25%, respectively [89] (Table 3). At termination, 2 weeks after  
 965 PN, the mean weight of right and left kidney was different for the groups with PN, independently of the treatment ( $P = 0.03$   
 966 for the Entresto® group and 0.005 for vehicle group) [89].

967 The treatment was well tolerated, and no side effects were reported after administration of Entresto® at a dose of 49/51  
 968 mg/daily. The final body weight of the pigs was not different between groups after 15 days [89] (Table 3).

| Characteristics      | PN + Entresto | PN + vehicle | Control + Entresto | Control + vehicle | P-value |
|----------------------|---------------|--------------|--------------------|-------------------|---------|
| Initial weight (kg)  | $31 \pm 3.2$  | $32 \pm 3$   | $35 \pm 2.5$       | $32 \pm 4$        | .5      |
| Terminal weight (kg) | $35 \pm 4$    | $36 \pm 1.5$ | $39 \pm 4$         | $37 \pm 3.5$      | .9      |
| Weight of            | $21 \pm 4$    | $21 \pm 2$   |                    |                   | .85     |

969

970

971

972

973

974

975

976

977

978 **Effect of Entresto® on baseline measured GFR and plasma creatinine in the four experimental groups.**

979 No differences in baseline GFR measurements were observed between the four groups. Pooled, measured GFR at baseline  
 980 from all pigs was  $65 \pm 4$  mL/min (n = 24). In accordance with this, baseline plasma creatinine concentration was the same in  
 981 the four groups of this study [89](Fig 4).

982

983

984

985

986

987

988

989

990


991

992

993

994

995 **Effect of Entresto® on measured GFR in pigs with and without partial nephrectomy and warm ischemia**



992 *Figure 4 Baseline values of measured GFR (mGFR) (A) and plasma*  
 993 *creatinine concentration (B) in the four experimental groups. No statistical*  
 994 *differences were found before interventions.*

996 Treatment with Entresto® at a dose of 49/51 mg daily versus placebo for 15 days improved total 99m TC-DPTA clearance 14  
997 days after right-kidney PN (Fig. 5). A mean difference of 23 mL/min (8.370-36.63 P = 0.0007) was found between the group  
998 of pigs undergoing laparoscopic PN (Fig. 5)[89]. At termination, left and right-kidney clearances were measured separately.  
999 In the group of PN + vehicle treatment, the right injured kidney exhibited lower GFR than kidneys in the sham surgery group  
1000 treated with Entresto®(Fig. 5). The total difference in GFR by clearance of 99<sup>m</sup> TC-DPTA was attributed predominantly to  
1001 improved clearance by the non-ischemic contralateral left kidney (Fig. 5). The difference in clearance between left intact  
1002 kidneys in the laparoscopic groups was significant; mean 16.7 mL/min (1.53-31.8) (P = 0.02) between the pigs receiving  
1003 Entresto® daily vs those receiving surgery + vehicle. Furthermore, the same mean difference was observed when comparing  
1004 left kidneys of pigs that underwent sham surgery and vehicle treatment (Fig.5)[89]. The largest single kidney GFR difference  
1005 was measured in the surgery group with Entresto®. The mean difference of clearance of the radiotracer between the right and  
1006 left kidney in the group with PN + Entresto® treatment for 15 days consisted in a 21 mL/min larger radiotracer clearance in  
1007 the left intact kidney (7-29 mL/min, P = 0.01; Fig. 5); the effect was not present in the group with laparoscopic surgery +  
1008 vehicle[89].

1009 With the intention to obtain an estimated value of baseline GFR clearance of 99<sup>m</sup> TC-DPTA from the right and left kidney, we  
1010 divided the initial clearance by two. This allowed us to analyse single-kidney GFR at baseline vs 14 days after surgery. We  
1011 found that the adaptive response of the left kidney in the group with PN and treatment with Entresto® was notorious. The  
1012 increase in clearance of 99<sup>m</sup> TC-DPTA from the left kidney was not only different from that of the injured right kidney (P =  
1013 0.0001); indeed, it also differed from the baseline values of the right kidney (P = 0.008) and left kidney itself (P = 0.0084;  
1014 Fig. 6)[89].The adaptative changes were not present in the group with PN+ vehicle treatment, and as expected; nor in control  
1015 group + Entresto® or the control group + vehicle ( Fig. 6)[89].

1016




Figure 5 Measured GFR by urinary clearance of  $^{99m}\text{Tc-DTPA}$  at baseline and after 15 days. At termination after 2 weeks, urine was collected from the right (RK) and left (LK) kidney by ureter catheter. A statistically significant difference was observed 2 weeks after PN between the groups receiving Entresto or vehicle. Significant difference at  $***P = .0007$  and  $*P = .02$ .

1017

1018

1019




Figure 6 Comparison of single-kidney GFR at baseline (estimated from total GFR) and after 2 weeks (measured for each kidney). (A) Groups with PN. (B) Groups with sham nephrectomy. Two weeks after PN, the adaptive response in the left kidney was significant in the group receiving Entresto. Significant difference at  $****P \leq .0001$  and  $**P = .036$ . LK, left kidney; RK, right kidney.

1020

1021

**Effect of Entresto® on filtration barrier injury in pigs with and without partial nephrectomy and warm ischemia**

No differences in total protein/creatinine ratio in urine from the injured kidney were observed between baseline values and values obtained after 14 days of laparoscopic PN and 60 min of warm ischemia in the group receiving treatment with Entresto® (Fig. 7A); nor was any difference observed from baseline to 14 days after surgery in left kidneys in the PN+Entresto® group. Opposite, a significant increase was seen in urine total protein/creatinine ratio 14 days after surgery in the right kidney in the group of PN +vehicle treatment ( $P < 0.05$ ; Fig.7A)[89]. For total protein, no difference between left and right kidneys was observed at 15 days in any of the groups. Using albumin as an injury marker, we discovered an increase in the albumin/creatinine ratio in urine from the right injured kidney 14 days after surgery compared with baseline ( $P = 0.01$ ; Fig.7B), but also in urine from the left kidney without ischemia in the group undergoing PN + vehicle ( $P = 0.005$ )[89]. This increase in albuminuria levels was not seen in the group of PN + Entresto®. It is important to note that the treatment with Entresto® did not change proteinuria or albuminuria levels in healthy (control) specimens (Fig.7 A and B)[89].




Figure 7(A) Total protein and (B) albumin: creatinine ratios in urine collected at baseline from bladder and after 2 weeks from the left kidney (LK) and the right kidney (RK). A significant increase was observed in the total urinary protein and albumin: creatinine ratios from the RK 2weeks after PN in the group receiving vehicle. Also, the left intact kidney showed an increase in albumin: creatinine ratio ( $P = .005$ ). Significant difference at  $**P = .005$  and  $*P = .01$ .



**Effect of Entresto® on mid-regional proANP (MR-proANP) in pigs with and without partial nephrectomy and warm ischemia**

Prior to the surgical aggression and at its termination, the plasma concentration of MR-proANP did not differ between the four experimental groups. Thus, Entresto® and sham surgery did not alter plasma ANP values. By contrast, 2 h after laparoscopic right-side PN with prolonged warm ischemia, MR-proANP increased significantly in plasma only in the Entresto® group compared with baseline values(P = 0.01; Fig.8)[89]. In both groups subjected to surgery and ischemia, plasma MR-proANP decreased close to baseline values after 15 days and was significantly lower than at 2 h after surgery (P = 0.003; Fig.8)[89].




Figure 8 The plasma concentration of MR-proANP in the experimental groups before and 2 h after surgery and at study completion after 2 weeks. Significant difference at \*\*P = .003 and \*P = .01.

**Effect of Entresto® on fractional electrolyte handling in pigs with and without partial nephrectomy and warm ischemia**

Fractional excretion of Na at baseline was 0.5-1% (Fig.9A) and there was no difference between the four groups. We found no difference in changes in fractional Na+ excretion at termination compared with baseline, or between kidneys between the sham groups receiving Entresto® or vehicle. A different scenario was seen at termination in the groups exposed to PN and warm ischemia (14 days after surgery). The fractional Na+ excretion increased above baseline in the injured kidneys from the surgery groups irrespective of treatment with Entresto®. In addition, only in the Entresto® group we did observe an increase in fractional Na+ excretion also in the non-injured left kidney (Fig.9A)[89]. The mean value of fractional excretion of K+ at baseline was 10-15%, and no differences were observed between pigs treated with Entresto® or vehicle. As for Na+, no differences were observed between fractional K+ excretion from left and right kidneys in sham groups after 15 days (Fig.9B).

Fractional  $K^+$  excretion increased in the injured right kidney in the group of pigs treated with Entresto<sup>®</sup>, but this effect was not found in the placebo-treated nephrectomy group[89].




Figure 9 Fractional excretion of (A)  $Na^+$  and (B)  $K^+$  at baseline and after 2 weeks from the left kidney (LK) and the right kidney (RK) in the four experimental groups. Treatment with Entresto increased fractional excretion of  $Na^+$  both from the RK and the LK 2 weeks after PN. Significant difference at  $**P = .001$  and  $*P = .04$ .

### Kidney injury molecule 1 (KIM-1) and kidney morphology images

No major pathological changes were observed; nor were any tubular casts or areas with tubular necrosis observed. At the glomerular level, we found that glomeruli were not sclerotic, vessels appeared with normal wall thickness and the interstitial compartment was not expanded. In only two kidneys we did observe signs of focal inflammation with infiltration of inflammatory cells in defined cortical areas[89].

Measurement of KIM-1 in tissue samples of right PN and TN after 15 days of treatment with Entresto<sup>®</sup> or vehicle did not show difference within or between groups[89].

**STUDY 3****Preoperative values**

The TN and PN groups had similar baseline characteristics. Patients in the PN cohort had a mean age of 58 years (SD 9) and a mean BMI of 27.7kg/m<sup>2</sup> (SD 5.2). Those in the TN group had a mean age of 62 years (SD 8) and a BMI of 29 kg/m<sup>2</sup> (SD 7.2)[43].

The functional volume of the sick kidneys (containing the tumour) was on average 176.2 cm<sup>3</sup> (SD 40.05) in the RN group and 132.2 cm<sup>3</sup> (SD 38.8) in the PN group; i.e. no statistical difference was seen between the groups (P = 0.1)[43].

The same tendency was observed when analysing the contralateral (healthy kidneys) in both groups, showing mean volumes of 169 cm<sup>3</sup> (SD 35,05) in the RN group and 158 cm<sup>3</sup> in the PN (SD 59.2) (P = 0.9; Table 4)[43] .

According to the American and European Urological Association guidelines, the size and location of the tumour should determine the choice between RN and PN[8, 9]. For that reason, and as expected, the volume of tumours of patients who underwent PN and TN differed statistically significantly (P = 0.001). The mean volume was 4.34 cm<sup>3</sup> (SD 2.3) in tumours in the PN group, and tumours in this group were predominantly small and exophytic. Opposite to this, the mean volume of tumours in the TN cohort was 34.4 cm<sup>3</sup> (SD 9.4) (P<0.001)[43].

|   | Total Nephrectomy | Partial Nephrectomy | P=(between groups) |
|---|-------------------|---------------------|--------------------|
| Age (years)                             | 62 +/- 8          | 58 +/-9             | 0.4                |
| BMI                                     | 29+/-7,2          | 27,7+/-5,2          | 0.68               |
| Pre op. Albumin/creatinine ratio (mg/g) | 32+/-45           | 26+/-30             | 0.92               |
| Pre op. Creatinine(μmol/l)              | 76+/-19           | 82+/-15             | 0.99               |
| Pre op mGFR (ml/min)                    | 98+/-15           | 84+/-8              | 0.1                |
| <u>Kidney volume cm<sup>3</sup></u>     |                   |                     |                    |
| Tumoral side                            | 176,2 +/-40       | 132,2+/-38,8        | 0.1                |
| Healthy side                            | 169+/-35          | 158+/-59            | 0.9                |
| Tumor volume cm <sup>3</sup>            | 34,4+/-9,4        | 4,34+/-2,3          | <0,001             |
| <b>Values expressed as mean and SD</b>  |                   |                     |                    |

Table 4 General characteristics of the cohort

1129

1130 **Volume changes on the contralateral kidney following partial and total nephrectomy.**

1131 The mean volume increase in the group of RN was 27 +/- 32% when compared with baseline volumes (Fig.10A)[43]. Similar  
 1132 increases were not seen in the PN group where the corresponding average volume increase was 4% (Fig 10B). The total  
 1133 kidney volume (sum of all healthy tissue) in patients in the RN group was mean 291±66 cm<sup>3</sup> in the preoperative period and  
 1134 mean 191±48 cm<sup>3</sup> after removal of an entire kidney (P = 0.0037). No statistically significant post-surgery changes were  
 1135 observed in patients undergoing PN (pre-surgery total volume 346±72 cm<sup>3</sup> vs. 325±93 cm<sup>3</sup> after surgery) (P = 0.79; Fig 10C  
 1136 and D)[43].




Figure 10 A Increase in volume after radical nephrectomy in the contralateral kidney. With only one exception, all patients experienced a significant increase in the remnant kidney ( $N = 11$ ,  $^* p=0.02$  by paired T test).

B In the partial nephrectomy group (B) there was no significant change in volume of the contralateral kidney ( $N = 9$ ). The figure shows the total kidney volume (sum of both kidneys) before and after patients were subjected to RN. After 12 months total volume was significantly reduced.  $^{**} p=0.003$ , ( $N = 11$ ).

C The figure shows the total kidney volume (sum of both kidneys) before and after patients were subjected to RN. After 12 months total volume was significantly reduced.  $^{**} p=0.003$ , ( $N = 11$ ).

D The total kidney volume remained stable in patients undergoing partial nephrectomy (PN) after 12 months. Total volume was not different from total volume before radical nephrectomy in C ( $N = 8$ ).

### Impact of nephrectomy on the filtration barrier and glomerular filtration rate

The values of p-creatinine and the albumin/creatinine ratio remained stable after surgery in both groups (Fig 11A and B)[43].

The mean preoperative value of GFR in the RN group was  $98.4 \pm 5$  mL/min. After removal of an entire kidney, a decrease to a mean of  $64 \pm 15$  mL/min one year after surgery ( $P < 0.001$ ) was observed. Based on the preoperative renography, a significant increase was seen in the GFR of the remnant kidney after TN in the present cohort. The mean preoperative single kidney had

a mean GFR of  $49 \pm 7.5$  mL/min, and the mean postoperative single kidney GFR was  $64 \pm 15$  mL/min ( $P = 0.012$ ). In the PN group, no difference between pre- and postoperative GFR was observed, and the mean reported GFR values for this group were  $84 \pm 8$  mL/min before surgery and  $75 \pm 14$  mL/min after one year of nephron-sparing surgery ( $P = 0.37$ )[43].




Figure 11 A After one year of radical or partial nephrectomy, there was no significant changes in p-creatinine ( $N = 19$ ,  $P = 0.30$ )

B The urinary albumin/creatinine ratio remained stable after one year of radical or partial nephrectomy ( $N = 19$ ,  $P = 0.97$ ).

**Relation between kidney hypertrophy and changes in the plasma hormones NT-proBNP, MR-proANP and aldosterone after nephrectomy**


NT-proBNP values showed a transient increase 24 hours after TN. The average preoperative NT-proBNP value was  $88.6 \pm 9$  ng/L which rose to a mean value of  $476 \pm 393$  ng/L 24 hours after surgery ( $P = 0.01$ ; Fig 12A). For MR-proANP, the peak of the increase also occurred after 24 hr of RN ( $P = 0.001$ ); but opposite NT-proBNP, all postoperative values (5, 21 days after surgery and 3 and 12 months after surgery) remained elevated after RN ( $P = 0.01$ ; 0.038; 0.035 and 0.049, respectively; Fig 12B)[43].

We found a positive correlation between the values of  $\Delta$  increase of NT-proBNP and volume hypertrophy after one day of TN ( $r = 0.42$ ; Fig 12C)

For MR-proANP, the positive correlation with volume ( $\Delta$  increase) was present at all the five postoperative timepoints with the strongest correlation after 12 months of TN ( $r = 0.78$ ;  $P = 0.02$ ; Fig 12D)[43]

1185 In the group of RN, the correlation between volume  $\Delta$  increase and the AUC for NT-proBNP and MR-proANP was also  
 1186 positive (0.25 and  $r = 0.5$ , respectively, Fig 12E and F)[43]. For aldosterone, the correlation with volume increase was  
 1187 negative at each postoperative timepoint (mean  $r = - 0.41$ ,  $P = 0.1$ )[43].

1188 The dynamic of NT-proBNP and MR-proANP following TN was not seen in the group of PN, and none of the timepoints  
 1189 were statistically different from one another[43].



1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
 Figure 12 A The curve shows plasma concentration changes with time of NT-proBNP (mean  $\pm$ SD in plasma) from patients subjected to radical unilateral nephrectomy ( $N = 11$  . \*\*:  $P = 0.0094$  by two-way ANOVA)

B The figure shows plasma concentration changes with time of MR-proANP (mean  $\pm$  XX) in the cohort of patients subjected to radical unilateral nephrectomy, ( $N = 11$ ). \*\*:  $P = 0.0011$ ( 1st 317 day p.o) , \*  $P = 0.01$  (5 days p.o) \*  $P = 0.03$  (21 days p.o) \* $P = 0.035$  (3 months p.o) \* $P = 0.04$  12 months p.o ) by two-way ANOVA.

C and D: The diagrams show the relation between the increase in kidney volume postoperatively at 12 months after nephrectomy and plasma concentration of NT-proBNP and MR-proANP at 12 months.

E and F The diagrams show the relation between kidney volume increase (delta) 12 months after nephrectomy and area under the curve (AUC) for the time course of plasma concentration changes of NT-proBNP and MR-proANP.  
1203

1209

1210

1211

1212 **Correlation between postoperative compensatory kidney hypertrophy and preoperative and delta GFR.**

A positive direct relation was observed between the volume increase and the preoperative values of GFR ( $\Delta$  increase value) ( $r = 0.40$ ). A strong positive correlation was also observed between single-kidney preoperative GFR values and GFR values after TN ( $r = 0.81$ ,  $P = 0.008$ ; Fig 13). By contrast, no positive relation was observed between increase in kidney volume and increase in GFR in the TN group ( $r = -0.14$ ;  $P = 0.7$ )[43].




Figure 13 The figure shows the relation between single kidney preoperative measured GFR (by 99m TC-DPTA and 51 Cr 325 EDTA clearance) and postoperative GFR in the patients subjected to radical nephrectomy (N=11) .



**DISCUSSION****STUDY ONE**

The rate diagnosis of AKI in patients admitted to the intensive care unit, after major surgeries or in direct interventions in the kidneys such as partial nephrectomies or renal transplantation could be around 15 -35%, being the underlying cause a disbalance between O<sub>2</sub> delivery and consumption at kidney level. The clinical consequence will be a higher need of dialysis and the possible development to chronic kidney disease also increasing the total healthcare cost[29, 30]. This scenario could explain the current need to find interventions that can decrease the occurrence of AKI and maintain the GFR without increasing the oxygen consumption in the postoperative phase. As reviewed in this article we enlightened that the natriuretic peptide pathway could be a valid and novel option based on its mechanism of action and the presence of natriuretic peptide receptors at afferent and efferent vessels at glomerular level in the kidney[67].

The activation of the NPRA at kidney level could benefit the vasodilatation at the arcuate and afferent arterioles and at the same time the contraction of the efferent arterioles and in this way contribute to maintain or increase the GFR[30].

The mechanism of action of NPs could explain why GFR is not affected negatively by continuous infusion of natriuretic peptides although a significant systemic blood-pressure-lowering effect was observed [10, 114, 115]. The advantages of the treatment with natriuretic peptides at the kidney level lose power due its short half-life of only 5 minutes which would demand continuous infusion. The atrial natriuretic peptide and the brain natriuretic peptide are degraded by the internalization at the Natriuretic peptide receptor C which is avid at the kidney level or by direct degradation of the neprilysin enzyme which has preference for ANP at an order of magnitude higher than for BNP[72, 73]. This problem prompted us and other researchers to think in alternative ways to increase the circulating level of natriuretic peptides and thus prolong the beneficial effects at kidney level. The combination of neprilysin inhibition plus angiotensin II blockers commercialized as Entresto® represents a valuable solution.

In experimental randomized trials Entresto® was able to prevent a decrease in blood flow at the kidney medullary level during and after major cardiac surgeries; increased 100% the blood flow at the vasa recta and 50% in the arcuate vessels[29, 116]. This notion may also explain why patients within the Entresto® group maintained GFR levels and avoided elevated plasma creatinine (above 2.5 mg/dl) in some trials[10, 114]. The meta-analysis by Dodey et al. of four studies using ARNI drugs also highlighted a renal benefit in patients with heart failure treated with these drugs[117]. Several studies found near optimal dose between 50 and 200 ng/kg/min and detrimental effects when the administration was above 200 ng/kg/min[94, 118].

1260 Another important factor to take into consideration is the concomitant effect of inhibition the angiotensin II AT1 receptors  
1261 that generates an increase in RBF and pressure related changes in GFR[7].

1262 In favour to the natriuretic peptide treatment some studies reviewed in this article remarked the fact that the patients  
1263 undergoing major cardiac surgery who received concomitant treatment of NP and furosemide required 75% lower doses of  
1264 the diuretic than controls during the post operative hospitalization, the length of stay was shorter and the increases in plasma  
1265 creatinine were significantly smaller in favour to the individuals receiving NP (21 vs 75% )[119].

1266 A well-known side effect of Entresto® is an increased albuminuria level. In the study by Jensen et al., it was shown that NPR-  
1267 A is not associated with mesangial cells but with podocytes in human kidney[67]. The albuminuria increase could be linked to  
1268 conductivity changes at this level; however, the increase seems to be transient, and levels normalise after treatment  
1269 discontinuation[10, 113, 120]. It is also seen that in DOCA-salt hypertensive mice, podocyte NPR-A has a significant and  
1270 marked protective action that may counterbalance effects of glomerular hypertension. Intriguingly, through elevated  
1271 ANP/BNP, Entresto® may therefore exert direct podocyte protection in CKD [10, 121]. Moreover, NPs could have an effect,  
1272 although indirect, at the kidney medullary level which is extremely susceptible to ischemia[29]. The explanation could lie in  
1273 the effect of the relaxation that Entresto® produces in the efferent arterioles and vasa recta at the juxtamedullary level[10, 78-  
1274 80].

## 1275 **Conclusion**

1276 The literature review showed that some of the properties of the NPs, such as a decrease in the level of plasma creatinine, an  
1277 improvement of postoperative GFR, and an anti-inflammatory function after warm ischemia-reperfusion syndrome, could be  
1278 interpreted as the beginning of a new era of use for these drugs to avoid kidney function disease after surgical and non-  
1279 surgical scenarios. The reviewed articles suggest that neprilysin inhibitors + ANG II blockers could have a determinant role in  
1280 reducing the number of patients who progress to ESKD. Larger experimental and/or clinical trials with a focus on kidney  
1281 function and outcomes are needed to make solid conclusions in this regard[10].

**STUDY TWO**

Until this study was conducted, only little information was available on the use of  $^{99m}\text{TC}$ -DPTA as a radiotracer to measure single-kidney GFR in pigs. Most of the previous studies in this field described other methods and radiotracers for measuring total GFR in pigs or another big animal like dogs [122-125]. The only previous model for measuring single-kidney GFR deployed MRI contrast enhancement and was tested only in dogs, and it was technically difficult to conduct[123]. We hence faced the challenge of creating a model for single-kidney determination of GFR; in this respect,  $^{99m}\text{TC}$ -DPTA proved to be feasible and the results of the pilot study confirmed the reproducibility of the method and allowed us to continue with the preclinical trial[89].

One of the goals of the study was to create an experimental situation close to the human setting of a partial nephrectomy using an animal model that could represent the kidney anatomy and function in the best possible way. Thus, the decision to choose which was the appropriate duration of ischemia time for the kidneys was challenging. First of all we considered the urological society recommendations to keep the ischemia time below 30 minutes[8, 9], furthermore we took the previous publications of Aarhus university group who developed a model of kidney ischemia injury using pigs as the animal model[87] and determined that to achieve a certain degree of kidney damage we should maintain the time of blood deprivation to the right kidney in around 60 minutes. In addition, the set up was created with the tough that the removal of around 1/3 of the kidney would have a detrimental effect.

We demonstrate that removal of around 1/3 of the right kidney plus deprivation of blood supply for 60 minutes have deleterious consequences for GFR and was able to generate damage at the filtration barrier by the finding of increasing levels of albuminuria. At light microscopy level we were not able to document glomerular damage in any of the groups.

A fact to remark was that the treatment with Entresto<sup>®</sup> enhanced the compensatory response of the contralateral kidney sufficiently to maintain acceptable GFR values and avoid an increase in p-creatinine[89]. Treatment with Entresto<sup>®</sup> for a total of 15 days also had protective effect on the filtration barrier, avoiding an increase of proteinuria or albuminuria in both kidneys, avoiding the increase of albuminuria that the hyperfiltration may cause in the non-damaged kidney and thus maintained stable levels of urinary albumin/creatinine ratio[89].

Activation of the NP receptor NPR-A increases cGMP in target cells and promotes kidney sodium and water excretion[126]. In preclinical models, activation of the NP receptor NPR-A has also been shown to increase RBF, especially in the outer medulla, which is extremely sensitive to changes in oxygen supply[10, 127-130]. This effect was seen also in preclinical

1311 experiments of high-risk surgery (cardiothoracic by-pass), where continuous NP infusion prevented changes in oxygen supply  
1312 at the medullary level of the kidney[29, 89].

1313 Treatment with Entresto® has previously been shown to protect the kidney in ischemia-reperfusion scenarios through  
1314 increasing of circulating levels of ANP[105, 107]. The reports by Ushijima et al. concluded that Entresto® had an anti-  
1315 proteinuric effect in 5/6 nephrectomised rats compared with treatment with valsartan alone which is in accordance with the  
1316 results of our study[89, 103]. One side effect of the compensatory increase in GFR of the contralateral kidney could be  
1317 albuminuria caused by the hyperfiltration effect, but this was also mitigated by the treatment with Entresto® [89].

1318  
1319 In some clinical trials, the use of Entresto® or continuous NP infusion increased creatinine clearance and urine flow, but, most  
1320 importantly, data showed that ANP infusion reduced sixfold the risk of dialysis[94, 95, 131]. Furthermore, ANP infusion  
1321 increased dialysis-free survival in patients admitted to intensive care unit or patients undergoing major surgery[95]. These  
1322 findings are in accordance with data from the present study, but our data suggest that particularly the healthy remaining tissue  
1323 responds to the intervention[89].

1324 Another important fact is that Entresto® plays a role in the protection of the filtration barrier, not only protecting the injured  
1325 kidney but also the contralateral kidney, avoiding the deleterious effects that the ischemia-reperfusion syndrome and  
1326 hyperfiltration could cause. Contrary to the group in which PN and vehicle was used as treatment, a deleterious effect at the  
1327 filtration barrier with an increase in proteinuria and albuminuria values was observed, not only in the right kidney but also in  
1328 the healthy (contralateral ) kidney[89].

1329 The present study did not allow as to identify a maintained increase in ANP plasma concentrations during treatment with the  
1330 drug as we expected. One possible explanation to this could be the fact that we were not able to measure active ANP in pigs  
1331 but only a stable translation product.

1332 None of the animals exposed to the treatment with Entresto® suffered side effects after administration of the drug and  
1333 variances as mean arterial pressure and weight remained stable[89].

1334 The use of pigs as animal model, demonstrated to be functionally and anatomically closer than rodents to the human anatomy,  
1335 and allowed us to translate techniques already used in humans (GFR measurement and partial nephrectomy) in the exact same

1336 way as in clinical settings. Moreover the pig kidneys demonstrated to be highly resistant to deleterious conditions as large  
1337 partial nephrectomy and prolonged deprivation of the blood supply[89].

### 1339 **Conclusions**

1340 The method to estimate GFR by plasma decay or clearance of  $^{99m}\text{Tc}$ -DPTA in pigs used in this study could be a useful  
1341 technique for future investigations with focus on kidney function and using pigs as animal model. A valid perspective would  
1342 be to elucidate if future investigations could arise to determinations of GFR using only late blood and urine samples, avoiding  
1343 a time-consuming process as it was in this study.

1344 After completion of this trial, we can enunciate that the treatment with the ARNI-class drug Entresto<sup>®</sup> for a period of 15 days  
1345 in pigs subjected to partial nephrectomy and warm ischemia protected the glomerular filtration barrier and improved the  
1346 functional adaptation of the non-damaged kidney.

1347 The treatment with Entresto could potentially represent a novel preventive pharmacologic therapy to protect kidney function  
1348 in different surgical scenarios, and not only on those with direct implication to the kidney.

1349 A weak point of the study was the small sample size, and therefore we conclude that larger studies would help to interpretate  
1350 in a better way the results that we obtained in this initial study.

1351 Human trials testing the drug will help to arise firm conclusions with respect to the clinical use of the drug.

**STUDY THREE**

Compensatory changes following PN or RN are well known and have been reported extensively in previous studies. However, the mechanism driving this process remain poorly investigated[44, 46-50].

In our study, we showed a significant volume increase in the remaining kidney tissue specially in the cohort of patients undergoing radical nephrectomy. The changes in the remnant kidney were related directly to tissue mass removal, pre-surgical GFR and post-surgery increase in plasma MR-proANP[43]. It should be noted that the sudden increase in ANP after kidney removal and the maintenance levels above baseline after one year of surgery could be interpreted as such the natriuretic peptides could play a significant role in post-surgery kidney structural hypertrophy. This, however, is purely associative and no causal relation can be concluded which would require intervention.

Additionally, confirming previous studies, we found that the preoperative GFR was positively correlated with postoperative volume increase and a compensatory GFR increase[43, 44, 46-50]. In experimental trials it was demonstrated that a humoral factor could be implicated in the post operative GFR adaptation after radical nephrectomy as the injection of plasma of recently nephrectomised rats into healthy specimens triggered a sudden increase in GFR[57].

In the study, we found a direct relation between MR-proANP and hypertrophy which could contribute causally to the volume increase after RN. Such a relation will await more direct testing and the present observational-associative relation does not demonstrate causality since another factors that might contribute to post operative kidney hypertrophy were not measured in this observational study [43].

Using patients from the present cohort, the original trial by Azawi et al. demonstrated a persistent increase in MR-proANP after 12 months of kidney removal, supporting the probable implication of NPs in the postoperative kidney adaptation [57].

The NPs could also act as protective agents at the filtration barrier of the kidney, maintaining a stable albumin/creatinine ratio. Experimental trials demonstrated that the treatment with Entresto<sup>®</sup> for a period could avoid increases in albuminuria and protected the contralateral kidney after ischemia reperfusion scenarios [10, 43].

Plasma aldosterone did not present postoperative changes, as demonstrated in previous investigations[57]. The fact that a negative correlation between p-aldosterone and the postoperative volume gain exists is compatible with reactive suppression of aldosterone and argues against aldosterone-driven kidney hypertrophy[43].

1389 The mechanism of compensatory kidney hypertrophy could lead to a volume increase in the contralateral kidney of up to 39%  
1390 in patients having undergone RN[44, 46-50]. Patients who experienced no contralateral kidney compensatory hypertrophy  
1391 were at higher risk of developing CKD[46]. A similar observation was done in different series of healthy, living kidney  
1392 donors. Those who experienced no early compensatory volume and GFR changes within a month had a tenfold higher risk of  
1393 developing cardiovascular disease and CKD than the general population[54-56], suggesting that the process of post-surgery  
1394 hypertrophy and GFR adaptation is a strong biomarker for a positive outcome.

1395 The urinary albumin-creatinine ratio was negatively correlated with those live donors who experienced CKH[132]. In our  
1396 study, the compensatory response was not associated with increases in the albumin creatinine ratio as observed previously[43,  
1397 54-56].

1398 The cohort of patients with PN experienced lesser changes. This may be explained by the limited removal of tissue since  
1399 tissue removal stimulates hypertrophy only temporarily. One year after PN, no significant change in GFR, kidney volume  
1400 and albumin/creatinine ratio was observed anymore[43].

## 1402 **Conclusion**

1403 This observational study could represent the first step towards the discovery of strong associations between postoperative  
1404 kidney hypertrophy and humoral factors that could lead to this process. The strengths of the original study were the  
1405 prospective design with a long follow up of one year after surgery representing enough time to stable hypertrophy levels.  
1406 The consecutive measurements at fixed timepoints provided a much better-integrated response measure for the correlation  
1407 analyses.

1408 The main weak points of this study are the small sample size included for the analysis and the observational nature. The  
1409 present observational study did not include living kidney donor patients, because they were not CT scanned routinely after  
1410 surgery.

1411 Longer randomized prospective clinical trials measuring natriuretic peptide level at fixed timepoints after surgery may help to  
1412 elucidate the possible correlation between these compounds and the magnitude of postoperative kidney hypertrophy.

**OVERALL CONCLUSIONS**

Previous investigations have shown that the use of natriuretic peptides or ARNI drugs could represent a new therapy to improve or maintain the renal function. The combination of effects of natriuretic peptides and concomitant blockage of ANG II AT1 receptors showed to be effective to decrease plasma creatinine levels and maintain GFR without increasing the filtration fraction. Moreover, neprilysin inhibitors + ANG II blockers could have a determinant role in reducing the number of patients who progress to ESKD[10].

The use of ARNI drugs , even though only for a short period of time, was able to demonstrate the protections of the filtration barrier and facilitated an improvement of the GFR by fast adaptation of the non-injured kidney after partial nephrectomy and prolonged warm ischemia time using an animal model closer to human anatomy and function than rodents[89].

Plasma levels elevations of endogenous atrial and brain natriuretic peptide after total nephrectomy could represent the first leap towards the discovery of strong associations between postoperative kidney hypertrophy and humoral factors that could be of vital importance to drive this process[43].

Human trials testing the drug will help to arise firm conclusions with respect to possible new clinical uses of the drug.

**PERSPECTIVES**

The natriuretic pathway and treatment with ARNI class drugs stills waits for larger randomized trials with focus on kidney function. Valuable information about GFR measurement methods, drug usage and proper time of blood deprivation to achieve kidney damage could be useful for future investigators. We should empathize that the aim of this study was not to elucidate the role that this drug could play in kidney cancer patients, the aim was to elucidate the role that the treatment could play in protection of renal function after different kind of surgeries and clinical scenarios. One of the obstacles for the use of natriuretic peptides could be that for achieving valuable outcomes, in terms of renal protection, the peptides may be administrated under continuous infusion due the short medium life of the compounds. This represents a challenging scenario for the implementation of home-based treatment, and therefore new ways of prolonging the action of the peptide could signify a valid approach. In that direction we can say that the combination of angiotensin II blockers plus neprilysin inhibitors (ARNI drugs) could play a determinant role.



1440 Probably is time to start thinking that the spectrum of the treatment with natriuretic peptides or ARNI drugs is beyond the  
1441 cardiovascular system, since it seems that they could play an important role in kidney protection and postoperative kidney  
1442 hypertrophy. Moreover, the treatment with ARNI drugs could potentially represent a novel preventive pharmacologic therapy  
1443 to protect kidney function in different surgical scenarios, and not only on those with direct implication to the kidney.

1444 After the development of a reliable method to measure GFR in pigs using a radiotracer, an additional point of valuable  
1445 interest for future investigations would probably be the estimation of GFR by plasma decay or clearance of  $^{99m}\text{TC}$ -DPTA  
1446 using only late blood and urine samples. This will definitively represent a time saving method.

1447 We strongly believe that the association between the use of natriuretic peptides or ARNI drugs and positive kidney outcomes  
1448 expressed in the three manuscripts that serve as main work for the realization of this PhD. could represent a starting point for  
1449 larger investigations that have the aim to elucidate the role of these drugs at kidney level and probably extend the current  
1450 clinical use of the compounds.

1451

1452

1453

1454

1455

1456

1457

1458

1459

1460

1461

## 1462 LIST OF REFERENCES

- 1463 1. Koeppen, B.M., *Renal Physiology : Mosby Physiology Series*. 2018: Elsevier - Health Sciences Division.
- 1464 2. Partin, A.W.D.R.R.K.L.R.P.C., *Campbell-Walsh-Wein urology*. 2021.
- 1465 3. Loutzenhiser, R., et al., *Renal autoregulation: new perspectives regarding the protective and regulatory roles of the*  
1466 *underlying mechanisms*. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology,  
1467 2006. **290**(5): p. 1153-1167.
- 1468 4. Milot, A., et al., *Prostaglandins and renal function in hypertensive patients with unilateral renal artery stenosis and*  
1469 *patients with essential hypertension*. J Hypertens, 1996. **14**(6): p. 765-71.
- 1470 5. Dunn, M.J. and V.L. Hood, *Prostaglandins and the kidney*. Am J Physiol, 1977. **233**(3): p. 169-84.
- 1471 6. Sraer, J.D., et al., *Role of the renin-angiotensin system in the regulation of glomerular filtration*. J Cardiovasc  
1472 Pharmacol, 1989. **14 Suppl 4**: p. S21-5.
- 1473 7. Huang, W.C., *Renal hemodynamic and tubular effects of angiotensins II and III*. Chin J Physiol, 1991. **34**(1): p. 121-  
1474 38.
- 1475 8. Ljungberg, B., et al., *European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update*.  
1476 (1873-7560 (Electronic)).
- 1477 9. Campbell, S., et al., *Renal Mass and Localized Renal Cancer: AUA Guideline*. J Urol, 2017. **198**(3): p. 520-529.
- 1478 10. Brignone, J., et al., *Protection of kidney function and tissue integrity by pharmacologic use of natriuretic peptides*  
1479 *and neprilysin inhibitors*. Pflugers Arch, 2021. **473**(4): p. 595-610.
- 1480 11. Petersen, A.C., et al., *The database of the Danish Renal Cancer Group*. Clin Epidemiol, 2016. **8**: p. 725-729.
- 1481 12. Al-Bayati, O., et al., *Systematic review of modifiable risk factors for kidney cancer*. Urol Oncol, 2019. **37**(6): p. 359-  
1482 371.
- 1483 13. Humphrey, P.A., et al., *The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-*  
1484 *Part B: Prostate and Bladder Tumours*. Eur Urol, 2016. **70**(1): p. 106-119.
- 1485 14. Simmons, M.N., et al., *Functional Recovery After Partial Nephrectomy: Effects of Volume Loss and Ischemic Injury*.  
1486 The Journal of urology, 2012. **187**(5): p. 1667-1673.
- 1487 15. Sahni, V.A. and S.G. Silverman, *Biopsy of renal masses: when and why*. Cancer Imaging, 2009. **9**(1): p. 44-55.
- 1488 16. Brierley, J., M.K. Gospodarowicz, and C. Wittekind, *TNM classification of malignant tumours*. Eighth edition. ed.  
1489 2017, Chichester, West Sussex, UK ;: John Wiley & Sons, Inc.
- 1490 17. Becker, F., et al., *Assessing the impact of ischaemia time during partial nephrectomy*. Eur Urol, 2009. **56**(4): p. 625-  
1491 34.
- 1492 18. Herr, H.W., *Surgical management of renal tumors: a historical perspective*. Urol Clin North Am, 2008. **35**(4): p.  
1493 543-9; v.
- 1494 19. Poletajew, S., A.A. Antoniewicz, and A. Borówka, *Kidney removal: the past, presence, and perspectives: a*  
1495 *historical review*. Urol J, 2010. **7**(4): p. 215-23.
- 1496 20. Licht, M.R. and A.C. Novick, *Nephron sparing surgery for renal cell carcinoma*. J Urol, 1993. **149**(1): p. 1-7.
- 1497 21. Zhang, X., *Laparoscopic and Robotic Surgery in Urology*. 1st 2020. ed. 2020, Singapore: Springer Singapore.
- 1498 22. Sotelo, R., J. Arriaga, and M. Aron, *Complications in Robotic Urologic Surgery*. Elektronisk udgave. ed. 2018,  
1499 Cham: Springer International Publishing.
- 1500 23. Secin, F.P., *Importance and limits of ischemia in renal partial surgery: experimental and clinical research*. Adv  
1501 Urol, 2008: p. 102461.
- 1502 24. Halazun, K.J., et al., *Warm ischemia in transplantation: search for a consensus definition*. Transplant Proc, 2007.  
1503 **39**(5): p. 1329-31.
- 1504 25. McDougal, W.S., *Renal perfusion/reperfusion injuries*. J Urol, 1988. **140**(6): p. 1325-30.
- 1505 26. Florack, G., et al., *Definition of normothermic ischemia limits for kidney and pancreas grafts*. J Surg Res, 1986.  
1506 **40**(6): p. 550-63.
- 1507 27. Jablonski, P., et al., *An experimental model for assessment of renal recovery from warm ischemia*. Transplantation,  
1508 1983. **35**(3): p. 198-204.
- 1509 28. Rosiello, G., U. Capitanio, and A. Larcher, *Acute kidney injury after partial nephrectomy: transient or permanent*  
1510 *kidney damage?-Impact on long-term renal function*. Annals of translational medicine, 2019. **7**(Suppl 8): p. S317-  
1511 S317.
- 1512 29. Kolsrud, O., et al., *Effects of atrial natriuretic peptide on renal function during cardiopulmonary bypass: a*  
1513 *randomized pig model*. Eur J Cardiothorac Surg, 2020. **57**(4): p. 652-659.
- 1514 30. Ricksten, S.E., G. Bragadottir, and B. Redfors, *Renal oxygenation in clinical acute kidney injury*. Crit Care, 2013.  
1515 **17**(2): p. 221.
- 1516 31. Richstone, L. and L.R. Kavoussi, *Re: The Impact of Ischemia Time During Open Nephron Sparing Surgery on*  
1517 *Solitary Kidneys: A Multi-Institutional Study: R. H. Thompson, I. Frank, C. M. Lohse, I. R. Saad, A. Fergany, H.*

- 1518 Zincke, B. C. Leibovich, M. L. Blute and A. C. Novick *J Urol* 2007; 177: 471–476. *The Journal of urology*, 2007.  
 1519 **178**(3): p. 1119-1120.
- 1520 32. Lane, B.R., et al., *Factors Predicting Renal Functional Outcome After Partial Nephrectomy*. *The Journal of urology*,  
 1521 2008. **180**(6): p. 2363-2369.
- 1522 33. Cao, X., et al., *Protective effect of lyophilized recombinant human brain natriuretic peptide on renal*  
 1523 *ischemia/reperfusion injury in mice*. *Genet Mol Res*, 2015. **14**(4): p. 13300-11.
- 1524 34. Zhang, Z., et al., *Acute Kidney Injury after Partial Nephrectomy: Role of Parenchymal Mass Reduction and*  
 1525 *Ischemia and Impact on Subsequent Functional Recovery*. *Eur Urol*, 2016. **69**(4): p. 745-752.
- 1526 35. Postalcioğlu, M., et al., *Association of Cold Ischemia Time With Acute Renal Transplant Rejection*. *Transplantation*,  
 1527 2018. **102**(7): p. 1188-1194.
- 1528 36. Salinas, S.J.F., et al., *Impact of Cold Ischemia Time in Clinical Outcomes in Deceased Donor Renal Transplant*.  
 1529 *Transplant Proc*, 2020. **52**(4): p. 1118-1122.
- 1530 37. Xing, M., et al., *Comparative Effectiveness of Thermal Ablation, Surgical Resection, and Active Surveillance for T1a*  
 1531 *Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked Population Study*.  
 1532 *Radiology*, 2018. **288**(1): p. 81-90.
- 1533 38. Van Poppel, H., et al., *A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic*  
 1534 *outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma*. *Eur Urol*,  
 1535 2011. **59**(4): p. 543-52.
- 1536 39. Motzer, R.J., et al., *Sunitinib versus interferon alfa in metastatic renal-cell carcinoma*. *N Engl J Med*, 2007. **356**(2):  
 1537 p. 115-24.
- 1538 40. Renner, A., et al., *Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma?* *J*  
 1539 *Kidney Cancer VHL*, 2019. **6**(1): p. 1-7.
- 1540 41. Onishi, T., et al., *Nephrectomy in Renal Carcinoma with Distant Metastasis*. *British Journal of Urology*, 1989. **63**(6):  
 1541 p. 600-604.
- 1542 42. Moll, F. and P. Rathert, *The surgeon and his intention: Gustav Simon (1824-1876), his first planned nephrectomy*  
 1543 *and further contributions to urology*. *World J Urol*, 1999. **17**(3): p. 162-7.
- 1544 43. Brignone, J., et al., *kidney volume increase following unilateral nephrectomy relates to plasma natriuretic peptides*.  
 1545 2022: under revision at BMC Nephrology journal.
- 1546 44. Rojas-Canales, D.M., et al., *Compensatory renal hypertrophy following nephrectomy: When and how?* *Nephrology*  
 1547 (Carlton), 2019. **24**(12): p. 1225-1232.
- 1548 45. Sugaya, K., et al., *Compensatory renal hypertrophy and changes of renal function following nephrectomy*.  
 1549 *Hinyokika Kyo*, 2000. **46**(4): p. 235-40.
- 1550 46. Chen, K.W., et al., *Compensatory Hypertrophy After Living Donor Nephrectomy*. *Transplant Proc*, 2016. **48**(3): p.  
 1551 716-9.
- 1552 47. Funahashi, Y., et al., *Relationship between renal parenchymal volume and single kidney glomerular filtration rate*  
 1553 *before and after unilateral nephrectomy*. *Urology*, 2011. **77**(6): p. 1404-8.
- 1554 48. Jeon, H.G., et al., *Prognostic significance of preoperative kidney volume for predicting renal function in renal cell*  
 1555 *carcinoma patients receiving a radical or partial nephrectomy*. *BJU Int*, 2012. **109**(10): p. 1468-73.
- 1556 49. Shehab, A.B., et al., *Early changes in volume and function of the remaining kidney after unilateral donor*  
 1557 *nephrectomy*. *Saudi J Kidney Dis Transpl*, 1994. **5**(4): p. 474-8.
- 1558 50. Takagi, T., et al., *Compensatory hypertrophy after partial and radical nephrectomy in adults*. *J Urol*, 2014. **192**(6):  
 1559 p. 1612-8.
- 1560 51. Kim, D.K., et al., *Two-year analysis for predicting renal function and contralateral hypertrophy after robot-assisted*  
 1561 *partial nephrectomy: A three-dimensional segmentation technology study*. *Int J Urol*, 2015. **22**(12): p. 1105-11.
- 1562 52. Mir, M.C., et al., *Parenchymal volume preservation and ischemia during partial nephrectomy: functional and*  
 1563 *volumetric analysis*. *Urology*, 2013. **82**(2): p. 263-8.
- 1564 53. Park, B.H., et al., *Tumor size is associated with compensatory hypertrophy in the contralateral kidney after radical*  
 1565 *nephrectomy in patients with renal cell carcinoma*. *Int Urol Nephrol*, 2016. **48**(6): p. 977-83.
- 1566 54. Kwon, H.J., et al., *Predictive Factors of Renal Adaptation After Nephrectomy in Kidney Donors*. *Transplant Proc*,  
 1567 2017. **49**(9): p. 1999-2006.
- 1568 55. Mjoen, G., et al., *Long-term risks for kidney donors*. *Kidney Int*, 2014. **86**(1): p. 162-7.
- 1569 56. Muzaale, A.D., et al., *Risk of end-stage renal disease following live kidney donation*. *JAMA*, 2014. **311**(6): p. 579-  
 1570 86.
- 1571 57. Azawi, N., et al., *Functional adaptation after kidney tissue removal in patients is associated with increased plasma*  
 1572 *atrial natriuretic peptide concentration*. *Nephrol Dial Transplant*, 2021.
- 1573 58. García-Ocaña, A., C. Peñaranda, and P. Esbrit, *Comparison of antiproliferative effects of atrial natriuretic peptide*  
 1574 *and transforming growth factor beta on rabbit kidney proximal tubule cells*. *Life Sci*, 1996. **58**(3): p. 251-8.

- 1575 59. Hussain, A., et al., *Differential effects of atrial and brain natriuretic peptides on human pulmonary artery: An*  
1576 *World J Cardiol*, 2019. **11**(10): p. 236-243.
- 1577 60. Matsukawa, N., et al., *The natriuretic peptide clearance receptor locally modulates the physiological effects of the*  
1578 *natriuretic peptide system*. *Proc Natl Acad Sci U S A*, 1999. **96**(13): p. 7403-8.
- 1579 61. Potter, L.R., et al., *Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic*  
1580 *applications*. *Handb Exp Pharmacol*, 2009(191): p. 341-66.
- 1581 62. Pandey, K.N., *Genetic Ablation and Guanylyl Cyclase/Natriuretic Peptide Receptor-A: Impact on the*  
1582 *Pathophysiology of Cardiovascular Dysfunction*. *Int J Mol Sci*, 2019. **20**(16).
- 1583 63. Goy, M.F., et al., *Evidence for a novel natriuretic peptide receptor that prefers brain natriuretic peptide over atrial*  
1584 *natriuretic peptide*. *Biochem J*, 2001. **358**(Pt 2): p. 379-87.
- 1585 64. Lowe, D.G., et al., *Human atrial natriuretic peptide receptor defines a new paradigm for second messenger signal*  
1586 *transduction*. *EMBO J*, 1989. **8**(5): p. 1377-84.
- 1587 65. Nagase, M., et al., *Tissue distribution and localization of natriuretic peptide receptor subtypes in stroke-prone*  
1588 *spontaneously hypertensive rats*. *J Hypertens*, 1997. **15**(11): p. 1235-43.
- 1589 66. Wilcox, J.N., et al., *Differential regional expression of three natriuretic peptide receptor genes within primate*  
1590 *tissues*. *Mol Cell Biol*, 1991. **11**(7): p. 3454-62.
- 1591 67. Frees, A., et al., *Natriuretic peptides relax human intrarenal arteries through natriuretic peptide receptor type-A*  
1592 *recapitulated by soluble guanylyl cyclase agonists*. *Acta Physiol (Oxf)*, 2020: p. e13565.
- 1593 68. Beavo, J.A. and L.L. Brunton, *Cyclic nucleotide research -- still expanding after half a century*. *Nat Rev Mol Cell*  
1594 *Biol*, 2002. **3**(9): p. 710-8.
- 1595 69. Suga, S., et al., *Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide,*  
1596 *and C-type natriuretic peptide*. *Endocrinology*, 1992. **130**(1): p. 229-39.
- 1597 70. Tripathi, S. and K.N. Pandey, *Guanylyl cyclase/natriuretic peptide receptor-A signaling antagonizes the vascular*  
1598 *endothelial growth factor-stimulated MAPKs and downstream effectors AP-1 and CREB in mouse mesangial cells*.  
1599 *Mol Cell Biochem*, 2012. **368**(1-2): p. 47-59.
- 1600 71. Kuhn, M., *Cardiac and intestinal natriuretic peptides: insights from genetically modified mice*. *Peptides*, 2005.  
1601 **26**(6): p. 1078-85.
- 1602 72. Brenner, B.M., et al., *Diverse biological actions of atrial natriuretic peptide*. *Physiol Rev*, 1990. **70**(3): p. 665-99.
- 1603 73. Pandey, K.N., *Endocytosis and Trafficking of Natriuretic Peptide Receptor-A: Potential Role of Short Sequence*  
1604 *Motifs*. *Membranes (Basel)*, 2015. **5**(3): p. 253-87.
- 1605 74. Eiskjaer, H., C.B. Nielsen, and E.B. Pedersen, *Pressure-dependent, enhanced natriuretic response to low-dose,*  
1606 *atrial natriuretic peptide infusion in essential hypertension*. *J Intern Med*, 1994. **236**(6): p. 665-74.
- 1607 75. Anderson, J.V., et al., *Atrial natriuretic peptide inhibits the aldosterone response to angiotensin II in man*. *Clin Sci*  
1608 *(Lond)*, 1986. **70**(5): p. 507-12.
- 1609 76. Heintl, E.S., et al., *Localization of natriuretic peptide receptors A, B, and C in healthy and diseased mouse kidneys*.  
1610 *Pflugers Arch*, 2023. **475**(3): p. 343-360.
- 1611 77. Bie, P., *Natriuretic Peptides and Normal Body Fluid Regulation*. *Compr Physiol*, 2018. **8**(3): p. 1211-1249.
- 1612 78. Lanese, D.M., et al., *Effects of atriopeptin III on isolated rat afferent and efferent arterioles*. *Am J Physiol*, 1991.  
1613 **261**(6 Pt 2): p. F1102-9.
- 1614 79. Marin-Grez, M., J.T. Fleming, and M. Steinhausen, *Atrial natriuretic peptide causes pre-glomerular vasodilatation*  
1615 *and post-glomerular vasoconstriction in rat kidney*. *Nature*, 1986. **324**(6096): p. 473-6.
- 1616 80. Veldkamp, P.J., et al., *Direct evaluation of the microvascular actions of ANP in juxtamedullary nephrons*. *Am J*  
1617 *Physiol*, 1988. **254**(3 Pt 2): p. F440-4.
- 1618 81. Swärd, K., F. Valson, and S.E. Ricksten, *Long-term infusion of atrial natriuretic peptide (ANP) improves renal*  
1619 *blood flow and glomerular filtration rate in clinical acute renal failure*. *Acta Anaesthesiol Scand*, 2001. **45**(5): p.  
1620 536-42.
- 1621 82. Valsson, F., et al., *Effects of atrial natriuretic peptide on acute renal impairment in patients with heart failure after*  
1622 *cardiac surgery*. *Intensive Care Med*, 1996. **22**(3): p. 230-6.
- 1623 83. Valsson, F., et al., *Effects of atrial natriuretic peptide on renal function after cardiac surgery and in cyclosporine-*  
1624 *treated heart transplant recipients*. *J Cardiothorac Vasc Anesth*, 1994. **8**(4): p. 425-30.
- 1625 84. Price, D.A., J. Okolicany, and T. Maack, *Renal receptors and effects of atrial natriuretic factor in compensatory*  
1626 *renal hypertrophy*. *Kidney Int*, 1992. **42**(1): p. 75-82.
- 1627 85. Blantz, R.C., et al., *Regulation of kidney function and metabolism: a question of supply and demand*. *Trans Am Clin*  
1628 *Climatol Assoc*, 2007. **118**: p. 23-43.
- 1629 86. Singh, P., et al., *Renal oxygenation and haemodynamics in acute kidney injury and chronic kidney disease*. *Clin Exp*  
1630 *Pharmacol Physiol*, 2013. **40**(2): p. 138-47.

- 1631 87. Pedersen, S.S., et al., *Cell injury after ischemia and reperfusion in the porcine kidney evaluated by radiolabelled*  
1632 *microspheres, sestamibi, and lactadherin*. EJNMMI research, 2013. **3**(1): p. 62-62.
- 1633 88. Ravlo, K., et al., *Early outcome in renal transplantation from large donors to small and size-matched recipients - A*  
1634 *porcine experimental model*. Pediatric transplantation, 2012. **16**(6): p. 599-606.
- 1635 89. Brignone, J., et al., *Protective effect of sacubitril/valsartan (Entresto) on kidney function and filtration barrier injury*  
1636 *in a porcine model of partial nephrectomy*. 2022: under revision in NDT journal.
- 1637 90. Brochner-Mortensen, J., *A simple method for the determination of glomerular filtration rate*. Scand J Clin Lab  
1638 Invest, 1972. **30**(3): p. 271-4.
- 1639 91. Jødal, L. and J. Brøchner-Mortensen, *Simplified methods for assessment of renal function as the ratio of glomerular*  
1640 *filtration rate to extracellular fluid volume*. Nucl Med Commun, 2012. **33**(12): p. 1243-53.
- 1641 92. slicer, D. *3D slicer software*. 2022 2022].
- 1642 93. Swärd, K., et al., *Differential effects of human atrial natriuretic peptide and furosemide on glomerular filtration rate*  
1643 *and renal oxygen consumption in humans*. Intensive Care Med, 2005. **31**(1): p. 79-85.
- 1644 94. Rahman, S.N., et al., *Effects of atrial natriuretic peptide in clinical acute renal failure*. Kidney Int, 1994. **45**(6): p.  
1645 1731-8.
- 1646 95. Swärd, K., et al., *Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized*  
1647 *placebo-controlled trial*. Crit Care Med, 2004. **32**(6): p. 1310-5.
- 1648 96. Gros, C., et al., *Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in*  
1649 *vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan*. Proc Natl Acad Sci U S A, 1989. **86**(19): p. 7580-4.
- 1650 97. Ibrahim, N.E., et al., *Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays*. J Am Coll Cardiol, 2019.  
1651 **73**(11): p. 1273-1284.
- 1652 98. Kahn, J.C., et al., *Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure*. Lancet, 1990.  
1653 **335**(8681): p. 118-9.
- 1654 99. Northridge, D.B., et al., *Effects of UK 69 578: a novel atriopeptidase inhibitor*. Lancet, 1989. **2**(8663): p. 591-3.
- 1655 100. Nougoué, H., et al., *Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in*  
1656 *chronic heart failure: a mechanistic clinical study*. Eur J Heart Fail, 2019. **21**(5): p. 598-605.
- 1657 101. Ruilope, L.M., et al., *Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II*  
1658 *receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study*. Lancet, 2010.  
1659 **375**(9722): p. 1255-66.
- 1660 102. Packer, M., et al., *Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat*  
1661 *Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)*. Circulation, 2002. **106**(8): p. 920-6.
- 1662 103. Ushijima, K., et al., *Prevention against renal damage in rats with subtotal nephrectomy by sacubitril/valsartan*  
1663 *(LCZ696), a dual-acting angiotensin receptor-neprilysin inhibitor*. Pharmacol Res Perspect, 2017. **5**(4).
- 1664 104. Benigni, A., et al., *Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy*.  
1665 Kidney Int, 2004. **66**(5): p. 1959-65.
- 1666 105. Moriyama, T., Y. Kanmura, and S.G. Lindahl, *Atrial natriuretic peptide attenuation of renal ischemia-reperfusion*  
1667 *injury after major surgery*. J Surg Res, 2016. **201**(1): p. 213-8.
- 1668 106. Jing, W., et al., *LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves*  
1669 *renal function beyond angiotensin receptor blockade in CKD*. Am J Transl Res, 2017. **9**(12): p. 5473-5484.
- 1670 107. Polina, I., et al., *Differential effects of low-dose sacubitril and/or valsartan on renal disease in salt-sensitive*  
1671 *hypertension*. Am J Physiol Renal Physiol, 2020. **319**(1): p. F63-F75.
- 1672 108. Desai, A.S., et al., *Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and*  
1673 *Reduced Ejection Fraction: A Randomized Clinical Trial*. Jama, 2019. **322**(11): p. 1-10.
- 1674 109. Haynes, R., et al., *Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease*.  
1675 Circulation, 2018. **138**(15): p. 1505-1514.
- 1676 110. Mc Causland, F.R., et al., *Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved*  
1677 *Ejection Fraction*. Circulation, 2020. **142**(13): p. 1236-1245.
- 1678 111. Rouleau, J.L., et al., *Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and*  
1679 *morbidity in patients with heart failure: IMPRESS randomised trial*. Lancet, 2000. **356**(9230): p. 615-20.
- 1680 112. Voors, A.A., et al., *Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart*  
1681 *failure and preserved ejection fraction*. Eur J Heart Fail, 2015. **17**(5): p. 510-7.
- 1682 113. Damman, K., et al., *Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart*  
1683 *Failure*. JACC Heart Fail, 2018. **6**(6): p. 489-498.
- 1684 114. McMurray, J.J., et al., *Angiotensin-neprilysin inhibition versus enalapril in heart failure*. N Engl J Med, 2014.  
1685 **371**(11): p. 993-1004.
- 1686 115. Taal, M.W., et al., *Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme*  
1687 *inhibition alone*. J Am Soc Nephrol, 2001. **12**(10): p. 2051-9.

- 1688 116. Kiberd, B.A., et al., *Effect of atrial natriuretic peptide on vasa recta blood flow in the rat*. Am J Physiol, 1987. **252**(6  
1689 Pt 2): p. F1112-7.
- 1690 117. Bodey, F., I. Hopper, and H. Krum, *Neprilysin inhibitors preserve renal function in heart failure*. Int J Cardiol, 2015.  
1691 **179**: p. 329-30.
- 1692 118. Lewis, J., et al., *Atrial natriuretic factor in oliguric acute renal failure*. Anaritide Acute Renal Failure Study Group.  
1693 Am J Kidney Dis, 2000. **36**(4): p. 767-74.
- 1694 119. Hobson, C.E., et al., *Acute kidney injury is associated with increased long-term mortality after cardiothoracic  
1695 surgery*. Circulation, 2009. **119**(18): p. 2444-53.
- 1696 120. Mullens, W. and P. Martens, *Exploiting the Natriuretic Peptide Pathway to Preserve Glomerular Filtration in Heart  
1697 Failure*. JACC Heart Fail, 2018. **6**(6): p. 499-502.
- 1698 121. Staffel, J., et al., *Natriuretic Peptide Receptor Guanylyl Cyclase-A in Podocytes is Renoprotective but Dispensable  
1699 for Physiologic Renal Function*. J Am Soc Nephrol, 2017. **28**(1): p. 260-277.
- 1700 122. Dhondt, L., et al., *Conventional Pig as Animal Model for Human Renal Drug Excretion Processes: Unravelling the  
1701 Porcine Renal Function by Use of a Cocktail of Exogenous Markers*. Frontiers in Pharmacology, 2020. **11**(883).
- 1702 123. Hackstein, N., J. Heckrodt, and W.S. Rau, *Measurement of single-kidney glomerular filtration rate using a contrast-  
1703 enhanced dynamic gradient-echo sequence and the Rutland-Patlak plot technique*. J Magn Reson Imaging, 2003.  
1704 **18**(6): p. 714-25.
- 1705 124. Luis-Lima, S., et al., *A Simple Method to Measure Renal Function in Swine by the Plasma Clearance of Iohexol*. Int  
1706 J Mol Sci, 2018. **19**(1).
- 1707 125. Worthley, C.S., M.J. Byrne, and R. Hickman, *Evaluation of Tc-99m-DTPA for renal clearance studies in the pig*.  
1708 Urol Res, 1988. **16**(6): p. 449-54.
- 1709 126. Wong, P.C., J. Guo, and A. Zhang, *The renal and cardiovascular effects of natriuretic peptides*. Adv Physiol Educ,  
1710 2017. **41**(2): p. 179-185.
- 1711 127. Goy, M.F., et al., *Evidence for a novel natriuretic peptide receptor that prefers brain natriuretic peptide over atrial  
1712 natriuretic peptide*. (0264-6021 (Print)).
- 1713 128. Lowe, D.G., et al., *Human atrial natriuretic peptide receptor defines a new paradigm for second messenger signal  
1714 transduction*. (0261-4189 (Print)).
- 1715 129. Nagase, M., et al., *Tissue distribution and localization of natriuretic peptide receptor subtypes in stroke-prone  
1716 spontaneously hypertensive rats*. (0263-6352 (Print)).
- 1717 130. Wilcox, J.N., et al., *Differential regional expression of three natriuretic peptide receptor genes within primate  
1718 tissues*. (0270-7306 (Print)).
- 1719 131. Sezai, A., et al., *Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic  
1720 kidney disease undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of  
1721 low-dose HANP Infusion Therapy during cardiac surgery) trial for CKD*. J Am Coll Cardiol, 2011. **58**(9): p. 897-  
1722 903.
- 1723 132. Miyauchi, T., et al., *Relationship between compensatory hypertrophy of the remnant kidney after donor nephrectomy  
1724 and albuminuria*. Clin Exp Nephrol, 2021. **25**(8): p. 913-914.



## SUMMARY

The prevalence of renal cancer is increasing, which may, among others, be due to a rise in the number of radiological investigations performed for other reasons, e.g., to determine the origin of abdominal pain or weight loss. Recent years have therefore seen an increase in the number of surgical interventions involving the kidneys. This trend and the rapid aging of the general population command careful considerations of possible treatments and strategies to protect the renal function during and after kidney surgery. Searching for a feasible therapeutic option that avoids or at least minimizes post-surgery loss of kidney function, we conducted studies to evaluate the role of natriuretic peptides and blockage of their degradation as this approach has shown promising results in the cardiovascular area.

The group of NPs counts three vasoactive peptides with a molecular weight below 10 kDa. that are structurally interrelated; they are atrial NP (ANP), B-type NP (BNP), and C-type NP (CNP). NPs are synthesised, stored and secreted at myocardiocyte level.

Aims:

- a) To perform a review to determine the potential benefits of the use of NPs and angiotensin-receptor-neprilysin inhibitor (ARNI) drugs to protect kidney function.
- b) To determine the feasibility of single kidney glomerular filtration rate (GFR) measure using <sup>99m</sup>Tc diethylenetriaminepentaacetic acid (DTPA) as radiotracer in a pilot study, using pigs as an animal model.
- c) To perform a randomised pre-clinical study investigating the action of LCZ696 at the kidney level after laparoscopic partial nephrectomy with prolonged ischemia time.
- d) To elucidate the role of NPs in the mechanism of kidney hypertrophy after kidney injury